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A Microfluidic Approach For Investigating The Role Of Blood Flow In Thrombosis
Abstract
Microfluidic devices provide a powerful platform for the study of blood biology due to their control of flow
geometry, shear flow conditions, and blood biochemistry. This thesis describes a series of microfluidic
approaches to investigate a range of pathological flow conditions and their effects on thrombus
formation. An impingement-post microfluidic device was designed to shear platelet-free plasma at
pathological rates to aggregate von Willebrand factor (VWF) into insoluble fibers held in place by a
micropost. VWF fibers were non-amyloid and resistant to ADAMTS13 and tissue plasminogen activator.
Factors XIIa and XIa were captured in VWF fibers during aggregation, and could initiate fibrin formation on
VWF. When whole blood was perfused over VWF fibers, platelets rolled, bound, and activated in a sheardependent manner on the fiber surface. To study the structure of thrombi formed in regions of flow
separation/reattachment in diseased arteries, another microfluidic device was designed to perfuse blood
creating a stagnation point on a thrombotic surface. For clotting over collagen/tissue factor surfaces,
platelet thrombi exhibited core-shell architecture with a P-selectin-positive, fibrin-rich core and a Pselectin-negative outer shell. VWF was present throughout the clot structure at both low and high shear
rates, but platelet and VWF deposition was markedly decreased when N-acetylcysteine was added. In
contrast, inhibition of fibrin polymerization did not change the overall structure of the thrombi, suggesting
VWF is more important to clot stability at stagnation points. N-acetylcysteine was found to reduce
deposition of VWF on collagen, but was not able to dissolve VWF fibers formed at pathological shear
rates in the impingement-post device. Shear-induced platelet activation (SIPA) on VWF was analyzed by
stretching VWF with bound platelets using increasing shear rate to measure platelet activation. As VWF
fibers stretched in shear flow, the proportion of activated platelets (measured by P-selectin exposure)
also increased. Platelets bound to sorbed, non-stretchable VWF displayed the same activation pattern,
suggesting fluid shear is more important in SIPA than VWF stretching. GPVI-bound soluble fibrin inhibits
platelet activation by collagen. Developing new microfluidic models of thrombosis may lead to a better
understanding of the mechanisms involved and produce diagnostic tests for thrombotic diseases.
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ABSTRACT

A MICROFLUIDIC APPROACH FOR INVESTIGATING THE ROLE OF BLOOD FLOW
IN THROMBOSIS
Bradley A. Herbig
Scott L. Diamond
Microfluidic devices provide a powerful platform for the study of blood biology due to their
control of flow geometry, shear flow conditions, and blood biochemistry. This thesis
describes a series of microfluidic approaches to investigate a range of pathological flow
conditions and their effects on thrombus formation. An

impingement-post

microfluidic

device was designed to shear platelet-free plasma at pathological rates to aggregate von
Willebrand factor (VWF) into insoluble fibers held in place by a micropost. VWF fibers were
non-amyloid and resistant to ADAMTS13 and tissue plasminogen activator. Factors XIIa
and XIa were captured in VWF fibers during aggregation, and could initiate fibrin formation
on VWF. When whole blood was perfused over VWF fibers, platelets rolled, bound, and
activated in a shear-dependent manner on the fiber surface. To study the structure of
thrombi formed in regions of flow separation/reattachment in diseased arteries, another
microfluidic device was designed to perfuse blood creating a stagnation point on a
thrombotic surface. For clotting over collagen/tissue factor surfaces, platelet thrombi
exhibited core-shell architecture with a P-selectin-positive, fibrin-rich core and a Pselectin-negative outer shell. VWF was present throughout the clot structure at both low
and high shear rates, but platelet and VWF deposition was markedly decreased when Nacetylcysteine was added. In contrast, inhibition of fibrin polymerization did not change
the overall structure of the thrombi, suggesting VWF is more important to clot stability at
v

stagnation points. N-acetylcysteine was found to reduce deposition of VWF on collagen,
but was not able to dissolve VWF fibers formed at pathological shear rates in the
impingement-post device. Shear-induced platelet activation (SIPA) on VWF was analyzed
by stretching VWF with bound platelets using increasing shear rate to measure platelet
activation. As VWF fibers stretched in shear flow, the proportion of activated platelets
(measured by P-selectin exposure) also increased. Platelets bound to sorbed, nonstretchable VWF displayed the same activation pattern, suggesting fluid shear is more
important in SIPA than VWF stretching. GPVI-bound soluble fibrin inhibits platelet
activation by collagen. Developing new microfluidic models of thrombosis may lead to a
better understanding of the mechanisms involved and produce diagnostic tests for
thrombotic diseases.
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CHAPTER 1: INTRODUCTION
1.1

Hemostasis and Thrombosis
Hemostasis is the process which causes bleeding to stop following damage to a

blood vessel [1]. The hemostatic response is primarily made up of the actions of platelets
and coagulation, which work in concert to reduce blood loss. When vessel injury exposes
subendothelial collagen and releases endothelial von Willebrand factor (VWF), platelets
bind and activate to trigger primary aggregation to the injury site [2]. The activated platelets
then release autocrine activators such as adenosine diphosphate (ADP) and thromboxane
(TXA2), which promote secondary aggregation, further slowing the loss of blood through
the injury site [2]. Simultaneously, exposed tissue factor (TF) initiates plasma coagulation
resulting in the generation of thrombin at the injury site, which further promotes platelet
activation, aggregation, and polymerization of fibrin. These processes strengthen the
hemostatic clot to halt blood loss.
Thrombosis, by contrast, occurs within diseased vessels where excessive clotting
and platelet buildup within the lumen of the vessel lead to obstructed blood flow and
potentially full vessel blockage [1]. It occurs in numerous life threatening diseases, such
as coronary artery disease [3], stroke [4], and venous thromboembolism [5]. Among the
main causes of thrombosis is disturbed blood flow [6], where both stagnating blood flows
and pathologically high blood flows can lead to the buildup of thrombi within a vessel. In
addition to the actions of platelets and coagulation described above, VWF circulating in
the plasma can exacerbate the formation of clots in these disturbed flows by aggregating
under high shear and extensional flow conditions and recruiting additional platelets [7].
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1.2

Platelets
Platelets are anucleate disc-shaped cells (2-3 µm in diameter when quiescent [8])

that are the primary drivers of hemostasis and thrombosis. When exposed to platelet
agonists, such as collagen or thrombin, platelets become activated through agonistspecific surface receptors. Activation manifests itself in two stages. First, there is an
increase in intracellular calcium, which causes the platelet cytoskeleton to spread and
create filopodial protrusions from its surface via myosin II and actin filament interactions
[9]. Second, activated platelets release a large number of species into the local
environment, such as ADP, TXA2, and alpha granules. Alpha granules contain a number
of clotting proteins, growth factors, and VWF, and express the adhesion molecule Pselectin on the surface of degranulated platelets [10]. Because of this, P-selectin is a
useful marker of platelet activation.
1.3

Plasma Coagulation
Plasma coagulation can be initiated by two distinct pathways: the contact (intrinsic)

pathway and the tissue factor (extrinsic) pathway (Figure 1-1), both of which converge
onto the common pathway to produce thrombin.
The contact (intrinsic) pathway is initiated by plasma contact with anionic surfaces
that activate factor XII to XIIa. After this initiating step, the cascade of activation continues
by XIIa activating factor XI to XIa, leading up to the activation of factor IX to IXa and the
formation of the intrinsic tenase, IXa/VIIIa. Following this reaction cascade, the intrinsic
tenase then activates factor X to Xa, beginning the common pathway. The intrinsic
pathway was thought to not be important in vivo because deficiencies in factors XII and XI
are not associated with abnormal hemostasis or bleeding [11], but recent evidence
2

suggests that it is important in thrombosis. This suggests factors XII and XI could be ideal
targets for anti-thrombotic drugs with low bleeding risk [12–14].
In the tissue factor (extrinsic) pathway, a disrupted endothelium, potentially from
trauma, plaque rupture, or other vascular injury, exposes tissue factor (TF) to the blood.
Circulating factor VII binds to TF in its activated form to form TF/VIIa, the extrinsic tenase,
which like the intrinsic tenase begins the common pathway by activating factor X to Xa.
Following the intrinsic and/or extrinsic pathways, the common pathway is initiated
by factor Xa, which along with factor Va in the prothombinase complex catalyzes the
activation of prothrombin to thrombin. Calcium ions play an essential role in assisting
coagulation, because both intrinsic tenase and prothrombinase complexes require
calcium ions and phospholipid surfaces to function [15].
Thrombin is the central protease in the coagulation cascade, and plays multiple
roles both in coagulation, fibrin formation, and platelet activation [15]. In the coagulation
cascade, thrombin is able to activate factor XI, causing a feedback loop which can selfamplify thrombin production [16]. Thrombin also is able to cleave fibrinogen to form fibrin
monomers, which then can be cleaved again by thrombin to polymerize into fibrin
polymers, which are either soluble or insoluble depending on chain length. Thrombin also
plays a significant role in platelet activation by cleaving PAR1 and PAR4 receptors on the
platelet surface [15].
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Figure 1-1: Simplified model of the coagulation cascade
Blood coagulation can be initiated by two distinct pathways: the contact (intrinsic) pathway
and the tissue factor (extrinsic) pathway. Both pathways merge to the common pathway,
where factor Xa catalyzes the conversion of prothrombin to thrombin, which amplifies
coagulation, polymerizes fibrin, and activates platelets.
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1.4
1.4.1

Von Willebrand Factor
Von Willebrand factor structure and multimer assembly
Von Willebrand factor (VWF) is a blood glycoprotein involved in both hemostasis

and thrombosis. VWF circulates in plasma in multimers that are variable in size. Each
VWF monomer contains 2050 amino acids, and consists of a number of domains with
specific binding sites and functions (Figure 1-2A). The D’/D3 domain binds factor VIII and
heparin in circulation, as well as participating in VWF multimerization. The A1 domain
binds to platelet GPIb, heparin, and collagen. The A2 domain, when partially unfolded by
shear flow, exposes the cleavage site for ADAMTS13. The A3 domain contains the
primary binding site collagen. The C1 domain contains the RGD motif enabling stable
binding to platelets via GPIIb/IIIa. The CK “cysteine knot” participates in VWF dimerization,
as well as binding to a number of growth factors.
VWF monomers form multimers in a multi-step process before secretion [17]
(Figure 1-2B). First, VWF monomers are N-glycosylated and form dimers at the CK
domain in the acidic pH of the endoplasmic reticulum. The VWF dimers are then joined by
disulfide bonds at the D’D3 domain in the Golgi apparatus to further multimerize. The VWF
multimers are assembled into a helical shape in the trans-Golgi network and Weibel
Palade bodies, which are unfurled when finally released into circulation by the endothelial
cell.
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Figure 1-2: VWF domain structure and multimerization
(A) Domain structure of VWF and common binding locations that are involved in
hemostasis and thrombosis. (B) VWF monomers assemble into multimers via
dimerization, followed by multimerization before secretion by endothelial cells. They can
then laterally aggregate into fibers via disulfide bonds along their length in high shear flow
conditions.
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1.4.2

Role of VWF in hemostasis and thrombosis
Although VWF is present in the α-granules of platelets, it is primarily released from

Weibel-Palade bodies in the endothelium as ultra-large VWF (ULVWF), described above.
To enter the plasma, the tethered ULVWF has to be released from endothelial cells (Figure
1-3). In hemostasis, these ULVWF strands that are tethered to activated endothelial cells
around an injury help attract platelets to the site of injury. ULVWF tethers under strain from
the shear flow of blood (potentially opening up the A2 domain) are then cleaved by a
metalloprotease called ADAMTS13. Once cleaved and processed by ADAMTS13, an
array of smaller VWF multimers circulate with molecular weight of ~1-~20 MDa in the
plasma. Plasma VWF also can participate in hemostasis by binding exposed collagen
under elevated shear flow, facilitating the binding of platelets to that collagen surface.
VWF also can play a significant role in thrombosis. Whenever VWF multimers in
plasma are exposed to high shear rates, such as while passing through a vessel stenosis
or over a partially occlusive thrombus, the extensional flow stretches out the VWF
multimers and exposes more hydrophobic domains along the protein [18], which cases
VWF to aggregate into fibers that are resistant to ADAMTS13 [19]. These fibers can bind
to the platelets on the top of the thrombus, which then allows them to recruit more platelets
to the thrombus surface. Because of the high shear rates seen when vessels reach ~75%
occlusion [20], VWF can drive nearly occlusive thrombi to occlusion [7]. Such extreme
shear flows may also be relevant to VWF assembly during hemorrhagic bleeding of
severed vessels.
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1.4.3

Diseases involving VWF biology
There are a number of genetic and acquired diseases surrounding VWF biology

with different clinical manifestations. Defects in VWF number and/or function can lead to
von Willebrand disease (VWD), which manifests in bleeding tendencies depending on the
qualitative and quantitative severity of the disease [21]. Type 1 VWF (making up 60-80%
of all cases) is a quantitative defect where VWF levels are detected at 20-50% of normal.
These patients are mostly asymptomatic, but occasionally exhibit bleeding following
surgery. Type 2 VWD (15-30% of cases) is a qualitative defect with four subtypes (A, B,
M, N) with varying bleeding tendencies. Type 2A VWD is quantitatively normal, but
qualitatively defective, resulting in only small multimers in circulations. Type 2B VWD is a
gain of function defect, where VWF binding to GPIb is enhanced, leading to spontaneous
platelet binding and clearance of both bound platelets and large VWF multimers, often
resulting in thrombocytopenia. Type 2M VWD is a qualitative defect that reduces the ability
of VWF to bind to GPIb, but does not affect multimerization. Type 2N VWD is a qualitative
defect in the binding of VWF to FVIII, which is often misdiagnosed as hemophilia A
because of VWF’s normal role of increasing FVIII half-life. Type 3 VWD is the most severe
form of VWD where no VWF is produced. These patients see severe life-threatening
bleeds similar to hemophilia A patients, highlighting the importance of VWF in hemostasis.
Acquired VWD can occur in patients with aortic valve stenosis [22] or high shear
medical devices such as left ventricular assist devices (LVADs) [23,24]. Acquired VWD
takes on the pathology of Type 2A, with an absence of large VWF multimers in circulation.
In patients with aortic valve stenosis, the high shear flow conditions at the stenosis led to
a significant reduction of >15mer VWF in plasma, and spontaneous bleeding occurred in
20% of patients as a result [22]. Replacement of stenosed aortic valves may be able to
8

reverse the effects of acquired VWD [22,25]. In LVADs, large multimers of VWF are
destroyed by mechanical stress and cleared, leading to a severe quantitative defect.
Multiple studies have shown that all patients with implanted LVADs have reduced high
molecular weight VWF multimers, and a majority of those patients had bleeding
complications [23,24]. Bleeding in LVAD patients is often GI bleeding and occurs many
months after onset of the acquired VWD, suggesting additional vascular pathological
mechanisms.
When there is a defect in ADAMTS13 function (thrombotic thrombocytopenic
purpura, TTP), circulating VWF multimers are much larger and form many micro-thrombi
in circulation. The resulting platelet-rich thrombi then have downstream effects, like
fragmenting red blood cells, causing thrombocytopenia, and causing ischemic damage to
organs [26]. TTP is an acute medical emergency with high fatality rates if not properly
diagnosed [27].
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Figure 1-3: VWF phenomena in low and high shear
VWF participates in both physiological and pathological processes based on exposure to
shear flow. At low shear rates (100-1500 s-1), ultra-large VWF (ULVWF) is released from
activated endothelial cells (1) and extend into the vessel lumen. After being stretched out
by shear flow, ADAMTS13 cleaves ULVWF into smaller multimers (2) that are released
into circulation (3). These multimers are useful in hemostasis, but when exposed to high
shear (>5000 s-1) pathologies such as vessel stenosis, severe thrombosis, or in high shear
medical devices (e.g. LVADs), circulating VWF multimers are stretched out, aggregate
into fibers, and can bind platelets to form thrombi (4).
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1.5

Hemodynamics and Adhesion Mechanics
Because platelets need to adhere to an injury site while they are flowing past in

the bloodstream, the receptors and ligands involved in adhesion and arrest at the injury
site need to be fast and strong enough to overcome the local fluid forces. In humans, blood
flows at different velocities (and resulting wall shear rates) depending on the anatomical
location, from 50-60 s-1 in the vena cava to 1000-5000 s-1 in some arterioles [28,29]. As a
result, different platelet receptors and protein ligands are responsible for stable adhesion
in different flow regimes. At shear rates below 500-800 s-1, platelets firmly bind to
subendothelial exposed collagen via α2β1 and glycoprotein VI (GPVI) [30,31]. Above 500800 s-1, however, the only receptor-ligand reaction with a high enough on-rate is VWF and
glycoprotein Ib (GPIb), which forms a “catch-slip” bond that manifests in platelet rolling
along VWF fibers [30,31]. In order to stably bind at high shear rates, platelet glycoprotein
IIb/IIIa (GPIIb/IIIa, also known as αIIbβ3) needs to activate via inside-out signaling and bind
to VWF. This interaction can only occur once the platelet has been slowed enough by
GPIb binding to increase its residence time on the VWF [32]. GPIIb/IIIa can also bind to
deposited fibrinogen and fibrin at the site of subendothelial exposure, which facilitates the
aggregation of platelets and leads to the formation of the hemostatic plug [33].
1.6

Microfluidics
One particularly useful platform for studying the extreme blood flows is

microfluidics. The vast array of microfluidic devices that have been developed and utilized
have been useful in many fields, but microfluidic devices are particularly useful for studying
extreme blood flows for their operational flexibility, control of fluid shear, and control of
flow geometry.
11

1.6.1

Operational flexibility
Microfluidics have been utilized extensively to design robust experiments to better

understand biological mechanisms under conditions of fluid flow. This platform technology
is particularly useful operationally because of its ease of use, versatility, scale, and control
of fluid conditions.
1.6.1.1 Ease of design and fabrication
The design and manufacturing of microfluidic devices is well-developed and
extensively described. The overall process is straightforward and allows for customization
of device features and design iteration at relatively low costs.
Device features are designed in computer-aided design (CAD) programs (e.g.
DraftSight or AutoCAD), which are then made into photomasks at a printing company (e.g.
OutputCity). Using these custom photomasks, the device features are transferred onto
silicon wafers using standard photolithography[34]. The resulting silicon wafers can then
be used as a reusable master mold to create polydimethylsiloxane (PDMS) microfluidic
devices. These devices are made by degassing PDMS prepolymer and curing reagents,
and curing them over the master wafer at 65°C for 3 hours. The temperature and time
used depends on the design of the microfluidic devices, as high temperatures tend to
shrink some features. Lower curing temperatures (45°C) and longer curing times (24
hours) followed by curing at higher temperatures can be used for devices with more exact
features[35]. After cooling, the molded PDMS can then be peeled off, cut into individual
devices (if the initial design includes multiple devices per mask), and modified with
appropriate hole-punches to create the inlets, outlets, and other ports in the final device.
Because microfluidic devices used to study pathological flows often contain complex
12

geometries, the ease of fabrication enables an iterative approach to device design and
experimental design.
1.6.1.2 Ease of detection
Another operational advantage of using microfluidic devices to study thrombosis
in pathological flows is the ease with which spatiotemporal changes in clot structure and
composition can be observed using a fluorescent microscope. Common fluorophores such
as phycoerythrin (PE), allophycocyanin (APC), and fluorescein isothiocyanate (FITC) can
be conjugated with antibodies against blood components like CD61 (platelets), CD62P (Pselectin), fibrin, or VWF to fluorescently track thrombosis in microfluidic devices using
different colors. This enables tracking of blood components and their relative
concentrations in thrombi by measuring relative intensity of the fluorescent signal
throughout the clot and over time.
1.6.1.3 Scale and blood volumes
One advantage that makes microfluidics particularly suited for use in studying
extreme blood flows is the relatively small volumes of fluid necessary to run each
experiment. Because the length scale of the channels on a microfluidic device are on the
micrometer scale, even high shear experiments can be run at relatively low flow rates on
the order of μL/min. Previous experimental technologies, such as parallel flow chambers,
required multiple liters of blood to run an experiment with the same time length and shear
rates that a couple milliliters could achieve in a microfluidic device. This scale advantage
also enables potential diagnostic applications where blood volumes are limited (i.e.
neonatal studies).
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1.6.1.4 Control of blood biochemistry
Microfluidics allow for significant control over blood biochemistry through the
addition of a variety of anticoagulants, inhibitors, and drugs. In contrast to in vivo studies,
where concentrations in blood are complicated by numerous factors, in vitro microfluidics
enable precise control of exogenous species concentration in the blood, providing insights
into the mechanisms involved. Blood begins the process of coagulation as soon as it is
exposed to a negatively-charged surface, so anticoagulation is particularly important in
microfluidic experiments. Numerous inhibitors of factors in the coagulation pathway are
used, as well as calcium chelators.
Direct inhibition of coagulation factors is a powerful tool in microfluidic studies of
pathological flows. PPACK, a direct and potent inhibitor of thrombin, is used to study the
role of platelets in thrombosis without the influence of coagulation. Apixaban is a Factor
Xa inhibitor which can be used to prevent the endogenous production of thrombin without
inhibiting any thrombin added to the experiment exogenously. Corn trypsin inhibitor (CTI)
blocks Factor XIIa, and can be used at various concentrations for different effects. At a
low concentration (~4 μg/mL), CTI prevents the contact activation from handling of blood
during the experiment, but allows the formation of thrombin over a thrombotic surface,
such as collagen. At a high concentration (~40 μg/mL), CTI is able to fully block the
intrinsic coagulation pathway, allowing the study of the extrinsic pathway
Calcium chelators, such as sodium citrate and ethylenediaminetetraacetic acid
(EDTA), prevent the calcium-dependent coagulation pathway from initiating. By adding
calcium ions back into the blood before or after introduction to the microfluidic device [36],
coagulation can be reinitiated and clotting can proceed. Note that EDTA should only be
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used in platelet-free experiments, because it has been shown to cause platelets to
dissociate their αIIbβ3 integrins [37].
Another manifestation of this advantage is in drug testing, where novel
anticoagulants, anti-platelet agents, and other drug candidates can be examined for their
effect on clot formation and dose-response relationship can be established. Because
overall blood volumes are low, smaller amounts of these additions are necessary to test
their effect on platelets and/or coagulation at sufficient concentrations.
1.6.2

Control of fluid shear
Microfluidics allow for precise control of fluid flow and shear conditions. Because

the mechanisms that dominate clotting differ between flow regimes and patterns, this
ability enables microfluidics to be a powerful platform in studying how pathological flows
affect clot formation. Stenosis devices in particular have been useful in studying the role
of VWF in high shear thrombosis.
Colace et al. used a stenotic-shaped microfluidic device (Figure 1-4A) that sheared
PFP or whole blood at pathological shear rates (> 30,000 s-1) and shear gradients over a
patch of collagen to study the interactions between sheared VWF, platelets, and collagen
[38]. Unlike typical viscometry experiments, these devices allowed for single-pass
perfusion of PFP or whole blood over the collagen, which allowed them to study how short
exposure to shear affects thrombotic potential.
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Figure 1-4: VWF deposition on collagen and platelets occurs in stenosis
microfluidic device
A) COMSOL simulation demonstrates severe pathological wall shear rate in the stenosis
device. B) EDTA-anticoagulated platelet-free plasma (PFP) was perfused over collagen
at 125,000 s-1, resulting the deposition of VWF fibers. C) VWF fiber deposition on collagen
was also observed in straight (non-stenotic) channels, suggesting shear gradients aren’t
required for VWF aggregation at extremely high shear rates. D) A steady-state platelet
clot on collagen was formed by flowing PPACK-anticoagulated whole blood at 200 s-1 for
1500 seconds, followed by perfusion of PPACK-anticoagulated PFP at 23,400 s-1. VWF
deposited in fibers on the platelet clot surface after 50 seconds. E) A schematic diagram
of VWF deposition in the D [38].
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Aggregation of VWF into fibers is driven by the high shear forces on plasma
upstream, which causes tumbling in flow and stretches out VWF fibers to expose
hydrophobic domains, which leads to lateral aggregation of VWF into fibers able to bind
to the collagen surface (Figure 1-4B). These fibers were also observed to be fully bound
to the collagen and did not relax when flow was stopped. Interestingly, the formation of
VWF fibers on collagen did not require a shear gradient (Figure 1-4C), which contrasts
with previous reports by Nesbitt et al [39]. It is possible that at lower shear rates, shear
gradients are more important to VWF elongation and aggregation, but Colace and
colleagues found that at extreme pathological shear rates, the high shear rate was
sufficient to induce VWF fiber formation on collagen. High wall shear rate may be the
dominant factor for VWF fiber bundle formation on a wall, whereas high shear rate gradient
or elongation rate may be the critical factor for VWF bundle formation in bulk flow.
When whole blood was perfused at pathological shear rates through the device,
VWF/platelet nets formed, rolled, and embolized across the collagen surface, an effect
blocked by anti-GPIb or the anti-αIIbβ3 inhibitor GR144053. When thrombi were allowed to
grow to steady state on a collagen surface at low shear, followed by high shear perfusion
of WB, VWF fibers formed on the surface of the clots through platelet GPIb (Figure 1-4DE). As a result, platelet recruitment was reestablished by increasing the GPIb/VWF
tethering via increased VWF aggregation at high shear on the thrombus surface. The
simple but extremely narrow stenotic channel shape over a collagen surface allowed for
the capitulation of these severely pathological environments without requiring large
volumes of blood.
Another common type of stenosis-shaped microfluidic device relies on a short
semi-circular region blocking 20-80% of the channel diameter to create high shear
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conditions and observe the resulting clot formation. Westein and colleagues [40] patterned
collagen in a striped pattern to compare the deposition of platelets and VWF at points
upstream, within, and downstream of the stenosis region. In this device, platelet
aggregation was enhanced in the stenotic outlet regions at 60-80% occlusion over a range
of inlet wall shear rates. Nesbitt and colleagues [39] used a fully-collagen-coated stenosis
microfluidic device to study the localization of platelets in low-shear zones at the
downstream face of forming thrombi. They found that soluble agonists were not required
for this aggregation in response to shear microgradients, which reinforces the crucial role
that VWF plays in thrombus formation following high shear stenoses.
Li and colleagues[41] also utilized a stenotic microfluidic device with a couple key
differences in device scale and thrombotic surface placement. The stenotic channel was
much larger than in the previously discussed stenosis devices, with a 750 μm channel
tapering to 250 μm. This matches more closely with pathologically relevant eccentric
constriction or stenosis, but requires the use of large volumes of blood, which reduces
applicability to point-of-care diagnostic devices. Second, the full channel of the device was
coated with collagen instead of localizing the thrombotic surface to patterned strips on the
glass surface. However, they did not observe any platelet clotting upstream or
downstream of the stenosis region, enabling it to be used for a highly systematic and
systemic analysis of the effect of aspirin (ASA) and eptifibatide (GPIIb/IIIa inhibitor) on
occlusive thrombosis and thrombus stability across a range of high shear rates.
In this study, it was found that shear rates have significant effects on both occlusion
time/dose-response curves for both therapies. For example, ASA had very little effect on
high shear occlusion times, while eptifibatide was able to reduce occlusion and increased
efficacy with dose at all shear rates tested. It was also found that high shear thrombi
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formed in the presence of ASA were 4 times more likely to detach than either untreated
or eptifibatide-treated controls. This and similar microfluidic devices that evaluate the
efficacy of antiplatelet therapies under a wide range of shear rates are valuable to
optimizing treatment models for high shear thrombotic diseases.
1.6.3

Control of flow geometry
Pathological flows occur in regions of the body with 3-dimensional geometry,

including at stenoses, bifurcations, and within thrombi. Microfluidics can recapitulate these
geometries to better understand clotting in pathological flows. Biomimetic stenoses,
stagnation point geometries, and pathologic interstitial flow all have been studied using
microfluidics.
One common criticism of traditions square microfluidic channels is that they do not
fully replicate the flow patterns found in round blood vessels. To address this, some groups
have used a cylindrical piece of material that PDMS can cure around, and which can then
be removed to leave behind a cylindrical-shaped microchannel. Mannino and
colleagues[42] used a 500 μm diameter optical fiber as their cylindrical mold, which they
modified to create the flow geometry of interest. To create a stenosis, a razor blade
covered with fine sandpaper was used to sand a fine notch out of the optical fiber, resulting
in the creation of a stenosis in the final PDMS device. Costa and colleagues[43] utilized
3D-printing to recapitulate the 3D vessel geometry and local blood flow patterns in a
microfluidic device. Although these devices do not fully recapitulate the 3D flow found in
larger blood vessels due to the low Reynolds number nature of microfluidics, the round
channels provide flow conditions more similar to the blood vessels than square channels
can.
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Using computed tomography angiography data of a coronary artery, both healthy
and stenosis models of the vessel were 3D printed and used as a template for PDMSbased soft lithography. The resulting channels were seeded with human umbilical vein
endothelial cells to form a confluent monolayer. When recalcified citrated WB was
perfused through the channels at an upstream wall shear rate of 1000 s-1, the healthy
geometry did not show any sign of thrombosis along the length of the channel for 15
minutes. The stenotic geometries (55% and 67% occlusion) both displayed thrombosis in
the downstream portion of the stenosis beginning at 2 minutes, with significant platelet
aggregation in the recirculation zone. Because shear rates in the stenosis reached
>10,000 s-1, VWF also likely played a role in recruiting platelets to the thrombus. The
innovative combination of 3D printing and traditional PDMS-based soft lithography
demonstrated how 3D hemodynamics can studied using microfluidic techniques.
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CHAPTER 2: MICROFLUIDIC DEVICE DESIGN
2.1
2.1.1

Microfluidic Design Process
Problem definition and brainstorming
Microfluidics is a powerful platform for studying a variety of topics, particularly

where fluid flow is involved. The process of designing a microfluidic device, either for a
single experiment or as a versatile multi-project device, begins with identifying which
capabilities are necessary for success. To mimic a piece of vasculature, what kind of shear
rates and geometry are needed? How will any resulting data be measured? The ease with
which microfluidic designs can be iterated allows some leeway for more specific questions,
but it helps to have a defined hypothesis to guide the design of the device.
Before starting to draw designs on the computer, begin by brainstorming ideas on
paper. The advantages of this are two-fold: drawing designs on paper is faster and allows
for easy recall, compilation, and modification of ideas. Drawing also enables spatial
awareness of where different features will be relative to each other and how they should
be arranged on the device. How will the device connect to any auxiliary pumps, actuators,
or pressure sensors?
2.1.2

Simulation and design
After arriving at one or more designs that enable proof-of-concept experiments,

draw the designs using a computer aided drafting (CAD) program, such as Solidworks or
Draft Sight, keeping in mind the scale of the CAD drawing. Begin by drawing the fluid
contacting channels, taking care that all of the lines surrounding a channel connect. In the
first iteration of the drawing (which will be used in simulations), do not draw any of the inlet
or outlet ports, or non-fluid-contacting features. A series of interconnected channels with
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lines capping the inlets and outlets is ideal for testing in computational flow dynamics
simulators, such as COMSOL. Save this file as a *.dxf for import into COMSOL.
In COMSOL, insert a work plane into a laminar flow simulation file and import the
microfluidic design onto the work plane. Extrude the plane to the desired channel height
within the limits of the photolithography to create a 3D structure of the channels. Adjust
the viscosity and density of the simulated fluid to match the desired fluid (e.g. blood or
platelet-free plasma). Select the flow path, and specify the inlets and outlets and their
respective flow rates or pressures (including those open to the atmosphere). Run the
simulation, and examine the velocity and pressure results to determine if the design
worked as intended. Other important characteristics of the flow, such as wall shear rate,
can be displayed through the results menus. If the design meets the intended
specifications, finalize the CAD drawing for the photomask to include inlet and outlet ports,
a seal surrounding the channels, and posts to enable vacuum sealing to glass slides.
Multiple device designs or duplicate designs can be included in the design to produce
multiple devices per wafer at a time.
2.1.3

Device testing and iteration
To translate the design into a physical device, first send the CAD drawing to a

photomask printing company (e.g. OutputCity), and specify that the microfluidic channels
should be clear on the mask and emulsion side should be down as viewed on the screen
(to improve photolithographic resolution). Once the mask is received (Figure 2-1A),
previously described soft lithographic techniques [44] can be used to fabricate a mold for
the microfluidic devices by preferentially patterning a negative photoresist (KMPR 1050,
MicroChem Corp.) on a silicon waver (D = 100 mm, WRS Materials). Spin the photoresist
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on the wafer to a height of 60 µm using a spin coater and soft bake it for 20 minutes. After
baking, place the substrate beneath the photomask and expose it to UV illumination to
crosslink the mask pattern onto the wafer. Bake it for an additional 4 minutes at 100°C,
and develop the photoresist using AZ® 300 MIF (AZ Electronic Materials USA Corp.) until
the mask pattern is visible on the wafer. Tape the wafer into a large petri dish container,
which will be used as the mold for the device (Figure 2-1B). Pour PDMS, with a base to
curing agent ratio of 10:1, over the mold, ensuring minimal introduction of air into the
polymer, and cure the PDMS for 2 hours at 80°C. Peel the now solid PDMS puck off of
the mold, and cut the devices to size. Inlet/outlet, vacuum, and other ports can be cut out
using core-punchers (Harris Uni-Core™), and multiple PDMS layers can be bonded
together using a plasma treatment to create the final devices (Figure 2-1C).
With completed microfluidic devices in hand, run the proof of concept experiments
determined during the design stage. With these results, decide which features work best,
which elements to omit, and iterate the design. Once a final, fully-functional design is
found, it is often helpful to create a wafer that includes multiple copies of that best design
to aid in experimental replication. Be sure to note any potential alterations that could be
made to the device after this stage, as they may lead to new designs that will enable future
studies.
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Figure 2-1: Microfluidic device production
(A) After finalizing the CAD drawing for the device, a photomask was printed using a
commercial service. (B) Using well documented techniques for photolithography, a wafer
with the microfluidic design was produced for use as a mold. (C) Final microfluidic device
is produced by pouring PDMS over the mold and baking to harden. Holes for inlets, outlets,
and vacuum lines were punched through the device, and the device was sealed to a glass
slide via a vacuum pump.
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2.2

Common Microfluidic Features
There are a number of common features used in microfluidic device design that

are useful for controlling the fluid path, adding a thrombotic surface, and making the device
more reusable. Stenosis-shaped channels (Figure 2-2A) are those which narrow in width
for a certain length of channel before expanding again to the full inlet width. This type of
channel is useful for increasing the shear rate in the narrowed part of the channel, with
the advantage of using less fluid volume to achieve a higher shear rate than a straight
channel would. When a microfluidic device runs in multiple stages (e.g. collagen is loaded
into the device before blood is introduced to clot on it), plugging inlets and outlets (Figure
2-2B) enables redirection of the fluid path to prevent the mixture of reagents before the
time of the experiment, or use of different channels at different times. Adding a thrombotic
surface by protein patterning on the glass slide is also a powerful technique (Figure 2-2C).
Collagen, tissue factor, VWF, fibrinogen, and other prothrombotic proteins [45] have been
used to initiate clotting within a defined area of the fluid channel, which helps to prevent
nonspecific clotting elsewhere in the device, and focuses the location of the clotting data
within a small area more easily monitored by fluorescent microscopy. Posts within flow
channels (Figure 2-2D) are commonly used for localizing polymerized fibrous proteins
(such as collagen [46,47] or VWF [19]) to provide a localized thrombotic surface on the
side wall of a microfluidic device. Finally channel bifurcations (and trifurcations, Figure
2-2E) at either the inlet or outlet enable control of fluid streamlines by introducing different
fluids (such as calcium buffer and whole blood) to the device at different locations in the
channel. This is because microfluidic flows have such low Reynolds numbers, so the flow
is strongly laminar. In creative combinations, these common microfluidic features allow
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the microfluidic platform to be versatile and useful for the study of hemostasis and
thrombosis.
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Figure 2-2: Common microfluidic features
(A) Stenosis channel demonstrated in the impingement post device [19]. (B) Inlets and
outlets can be plugged to change fluid flow paths. For example, in the stagnation point
device [47], after collagen has been introduced into the device, the collagen inlets and
outlet are plugged using flat syringe tips stuffed with putty to prevent air flow. (C) Collagen
patterned on the glass slide to serve as a thrombotic surface in a flow channel [45]. (D)
Posts in the side view microfluidic device [46] provide a place for collagen fibers to wrap
around and immobilize. (E) A trifurcation inlet allows for fluid streamline control [36,48].
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2.3

Device Design Considerations
When designing a microfluidic device, there are two categories of common issues

that need to be addressed with the design: channel size/position and fluid flow effects.
In determining the size and position of channels on a microfluidic device, it is
important to think about both the minimum allowable dimension size for the photomask
printing and photolithography technique used. In the technique described above, details
smaller than 15 µm do not appear in the final device reliably. Second, since data
acquisition from a microfluidic device is usually done via fluorescent microscope, it is
important to design the region of interest (where the data will be captured, e.g. platelet
signal on a collagen patch) within as few microscope frames as possible, allowing
optimization of both the image and time resolution of the data. For example, in the
impingement post device discussed in Chapter 3, two adjacent channels are positioned
such that both are visible in the same microscope frame without merging, allowing for
higher throughput studies to be conducted.
Though the COMSOL simulations discussed above are useful in designing
channels, a few fluid issues arise in the experimental setup that don’t appear in the
simulation. First, when fluid is pushed through the device by a syringe pump and has more
than one possible path, the resistances over those paths will determine what fraction of
fluid flow progresses through each. If the device is designed to have equal resistance over
two paths, however, the pushed fluid will often proceed down one path due to small
pressure instabilities in the fluid. Whenever tight control of the bifurcation of fluid is needed,
it is useful to instead withdraw fluid from both outlets rather than pushing fluid from the
inlet to overcome this pressure instability. Second, whenever the microfluidic device has
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very small dimensions involved (e.g. a gap of <30 µm), there may be issues with clogging
the device. Even if the dimension is large enough for all blood cells to pass through,
aggregated debris from the air or filtered solution can clog and divert flow, or block the
region of interest, leading to obscured data. To overcome this, be careful to filter all
components in entering the device, and include a large number of replicates on one chip
to help collect enough data from non-clogged channels only.
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CHAPTER 3: PATHOLOGICAL VWF FIBERS RESIST TPA AND ADAMTS13 WHILE
PROMOTING THE CONTACT PATHWAY AND SHEAR-INDUCED PLATELET
ACTIVATION
3.1

Introduction
Severe coronary stenosis can cause extremely high shear rates, boundary layer

detachment, and flow recirculation zones downstream of the stenosis [49]. Only when the
stenosis exceeds ~75% occlusion does the flow resistance cause symptoms of angina
[20]. Stenotic coronary flows can even create rare instances of fluid mechanical
turbulence, especially during the deceleration phase of diastole [50]. At physiological
arterial shear rates, von Willebrand Factor (VWF) is essential for platelet capture via
glycoprotein Ib (GPIb) binding followed by adhesion stabilization via IIb3 binding to
VWF [51]. However, in pathological flow conditions with shear rates exceeding 5000 s -1,
VWF undergoes a complex coil-stretch transition to an extended conformation capable of
association [52]. This complex aggregation process occurs both axially and laterally to
form thick and long fiber bundles of greater than 100 μm in length [52]. The largest soluble
VWF species above ~ 5 x 106 MW display remarkable platelet adhesivity [53,54] and may
incorporate preferentially into VWF fibers. Additionally, extreme shearing flows in certain
left ventricular assist devices cause an acquired von Willebrand’s Disease with associated
bleeding risks [23].
Distinct from unprocessed VWF fibers secreted acutely from endothelium
[40,55,56], intrathrombic VWF fibers deposited during arterial thrombosis are likely derived
from ADAMTS13-processed plasma [7]. Microfluidic devices have enabled studies of
plasma-derived VWF unfolding and fiber formation on collagen at extreme shear
conditions using small volumes of blood or plasma. Colace et al. [38] utilized a stenosis
shaped microfluidic device to show VWF fiber formation and embolic VWF-platelet
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aggregates on collagen mediated through GPIb and IIb 3. Kragh et al. [57] also
demonstrated self-assembly of VWF fibers on a collagen or VWF surface capable of rolling
platelet aggregate formation under high shear rates. However, collagen in these VWF
studies can have strong confounding effects on platelet function via activation of platelet
GPVI. Other studies have coated the surfaces of glass slides [40] or microspheres [39]
with plasma-derived VWF to explore how platelet thrombi formed on VWF-coated surfaces
in response to shear. However, surface sorbed VWF from solution [54] lacks the structural
and biomechanical attributes of VWF fibers formed from plasma at pathological shear.
A stenotic microfluidic channel was designed with a micropost positioned in the
middle of flow field to capture soluble VWF multimers as they experienced extreme shear
rates within the device. Using a microfluidic design capable of generating fibrous VWF
from plasma in the absence of collagen or endothelium, the unique mechanical and
biological attributes of VWF fibers were investigated. We report the first determination of
the VWF fiber elastic modulus, the role of VWF fibers in promoting contact pathway
function, and the thrombolytic resistance of VWF fibers to tissue plasminogen activator
(tPA).
3.2
3.2.1

Materials and Methods
Blood collection and preparation
Whole blood was drawn from healthy volunteers who self-reported as free of any

bleeding disorders or disease, as well as free of oral medication for at least 10 days. All
blood was collected in accordance with the University of Pennsylvania’s Internal Review
Board. Depending on the experiment, blood was anticoagulated with 5 mM EDTA (Sigma,
St. Louis, MO) to chelate calcium, 100 μM D-Phe-Pro-Arg chloromethylketone (PPACK,
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Haematologic Industries, Essex, VT) to inhibit thrombin and FXIIa, 1 μM apixaban to inhibit
Factor Xa, and/or corn trypsin inhibitor (CTI, 4 μg/mL or 40 μg/mL) to inhibit Factor XIIa.
GR144053 (2 M) was used in some experiments to inhibit IIb3. Platelet-free plasma
(PFP) was generated by centrifugation of whole blood (300g, 10 min) to create plateletrich plasma (PRP), followed by PRP centrifugation (10,000g, 5 min) to create platelet-poor
plasma (PPP), followed by PPP centrifugation (10,000g, 5 min). Trypsin (Life
Technologies, Grand Island, NY), ADAMTS13 (R&D Systems, Minneapolis, MN), plasmin
(Haematologic Technologies, Inc., Essex Junction, VT), and tPA (Abcam), and fluorogenic
substrates FRETS-VWF73 (Anaspec, Fremont, CA) and Boc-VPR-MCA (R&D Systems)
were also used. Anti-CD41 and anti-CD62P (BD Biosciences, San Diego, CA) are both
PE labeled. Anti-Factor alpha XIIa antibody (Abcam) was labeled using an Alexa Fluor®
647 Protein Labeling Kit (Life Technologies). FXII-deficient plasma (Haematologic
Technologies, Inc.) was manufactured from normal citrated human plasma that was FXII
immunodepleted to <1% activity. The antibody 14E11 was a kind gift from Dr. Andras
Gruber (Oregon Health and Science University, Portland, OR).
3.2.2

Device design and fabrication
Microfluidic devices were fabricated out of polydimethylsiloxane (PDMS)

(Ellsworth Adhesives) using previously described soft lithography techniques [44,58,59].
The device design consisted of a 500 μm channel that rapidly narrowed to a 60 μm wide
stenosis region, which extended for 1000 μm before expanding again to a 500 μm wide
channel. The channel height throughout the device was 60 μm. In the middle of the
stenosis region, a 30-μm square micropost extended across the entire height of the
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channel, providing a physical location for VWF fiber capture and growth without the use
of collagen.
3.2.3

Computational fluid dynamics
Finite element simulations were conducted using COMSOL Multiphysics

(Burlington, MA) to predict the plasma or blood flow profile (1.38 cP or 3.39 cP viscosity,
respectively [60]) around the post, with and without a VWF deposit at steady flowrates of
1 to 20 L/min. Computational fluid dynamics simulation provided wall shear rates at
regions of interest: (1) average centerline wall shear rate in the stenosis region upstream
of the post, which is a metric of the shear force on VWF in solution to extend into its active
form before reaching the post, and (2) wall shear rate on the micropost, which is a metric
of the extensional force on fibers that multimerize with other VWF already tethered on the
post.
3.2.4

Microfluidic flow experiments
Devices were sealed to Sigmacote® (Sigma-Aldrich)-treated glass slides. The flow

channels were blocked with 5% bovine serum albumin (BSA, Sigma-Aldrich) for 30 min
before sample perfusion. Whole blood or PFP (under various specified anticoagulation
conditions) were perfused through the device using a syringe pump (Harvard Apparatus,
Holliston, MA). The microfluidic device was mounted on an Olympus IX81 inverted
microscope equipped with a charge-coupled camera (Hamamatsu, Bridgewater, NJ).
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3.3
3.3.1

Results
Pathological shear rates generate fibrous VWF from plasma on a capturing
micropost

A PDMS microfluidic device with 8 individual lanes was vacuum-sealed to glass where
each lane converged stenotically to a 60 m wide x 60 m high flow path that then
impinged on a 30-m square micropost (Figure 3-1A-B). Fluid streamlines were visualized
with 10 μm fluorescent beads (5 μL/min) revealing the computationally-expected flow
stagnation points on the front and back of the micropost (Figure 3-1C-D). For a flow rate
of 5 L/min, wall shear rate increased from 0 at the front centerline stagnation point to
>10,000 s-1 at the front corners of the micropost, resulting in a wall shear rate gradient of
~3.33 x 106 s-1/cm. The peak wall shear rates along the side walls of the micropost were
calculated at 20,000 s-1 for a flow rate of 5 L/min (Figure 3-1E). As plasma impinges and
flows around the post, a rapidly increasing extensional force is expected to help to orient
fibers to maximize their contact with the post, increasing the probability of a VWF fiber
sticking. Perfusion of EDTA-PFP resulted in VWF fiber formation at 5000, 8000, and
10000 s-1 upstream centerline wall shear rate (Figure 3-2A). The thickness of the fibers at
5 min increased 5-fold (p<0.01) from 2.5 μm to 12.5 μm as the wall shear rate increased
from 5000 to 10000 s-1 (Figure 3-2B). Flow-aligned VWF fibers were stretched in the
direction of flow as they formed since an acute reduction in flow triggered an observable
retraction. To examine the elastic properties of VWF, a small post-attached single VWF
fiber was formed at 10000 s-1 (13.7 L/min) and then interrogated mechanically by
alterations in the prevailing flow rate. Once the small fiber formed from plasma, the flow
was switched to HBS and reduced to 4 μL/min and HBS was perfused over the tethered
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VWF fiber. The flow rate was increased stepwise from 4 to 13 L/min, allowing the fiber
to equilibrate at each flow rate before measuring its length (Figure 3-2C). The wall shear
stress and total force on the surface of the fiber as it was stretched was estimated with an
axial annular flow approximation over a cylindrical fiber. Assuming the volume of the fiber
was conserved over the experiment, the length of the fiber after each stretch was used to
determine its new diameter. By integrating the drag force per length over the entire length
of the fiber, the total stress on the fiber was calculated, assuming the initial 4 μL/min fiber
as “relaxed” for the purpose of comparison to the “stretched” forms of the fiber under
higher flow rates. Through this estimation, the calculated elastic modulus of fibrous
plasma-derived human VWF was ~50 MPa (Figure 3-2D), quite similar to the fibrin fiber
elastic modulus in FXIIIa-crosslinked plasma clots [61].
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Figure 3-1: Microfluidic device design and characterization
(A) Stenosis-shaped channel with a small post located in the middle of flow. (B)
Macroscopic device design allows for multiple channel VWF fiber generation. (C)
Fluorescent beads were perfused past the post and imaged with a 25 ms exposure to
visualize streamlines within the device. (D) COMSOL-simulated streamlines depicting
diverging flow upstream of the post. (E) Wall shear rate heat map flow for a flow rate of 5
μL/min.
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Figure 3-2: VWF fiber characteristics and mechanical properties
(A) Representative immunofluorescent images of VWF fibers that were generated by
flowing EDTA PFP at 5000, 8000, and 10000 s-1 upstream wall shear rate for 5 min from
initial fiber capture. (B) Average fiber width was measured at 30 μm below the post at each
shear rate. (C) A single VWF fiber was captured on the post by flowing EDTA PFP at 5000
s-1 for 30 s from initial fiber capture. The fluid was then switched to HBS to prevent
additional VWF fiber growth and the flow was reduced to 4 μL/min. The flow rate was
increased stepwise and the fiber was allowed to equilibrate between steps. (D) Stressstrain plot for the single VWF fiber in C. Stress was calculated by assuming axial annular
flow around the fiber to calculate the drag force on the fiber. Strain was calculated
assuming the 4 μL/min case was “at rest” and each subsequent flow rate as stretched
forms at constant fiber volume.
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3.3.2

Fibrous VWF is non-amyloid, tPA-resistant, but plasmin-sensitive
In order to further characterize the VWF fibers produced by micropost capture,

various proteases/surfactants were assessed. Both 0.25 % trypsin and 2% SDS quickly
dissolved fibrous VWF (Figure 3-3A-B), demonstrating that insoluble VWF fibers were
non-amyloid. In contrast, 30 mM N-acetylcysteine was not able to dissolve already formed
VWF fibers (not shown). However, when ADAMTS13 (50 nM) was added to plasma and
perfused over VWF fibers, no observable degradation took place at 10000 s-1 within 480
s (Figure 3-3C). ADAMTS13 activity was confirmed with the fluorogenic substrate FRETSVWF73. VWF fibers (formed from plasma treated with apixaban and PPACK to prevent
any fibrin incorporation) were resistant to 100 nM tPA in apixaban/PPACK-treated plasma
(Figure 3-3D) demonstrating that VWF does not serve as a cofactor to enhance tPA
activity toward plasminogen. However, 1 μM plasmin readily dissolved fibrous VWF fibers
formed from EDTA-treated PFP in 40 s (Figure 3-3E), a result consistent with that
observed for trypsin. Both plasmin and trypsin are fairly non-specific peptidase family S1
(chymotrypsin family, clan PA) members [62]. Also, soluble VWF is a known substrate for
plasmin [63].
3.3.3

Fibrous VWF accumulates procoagulant factors to drive fibrin formation
To analyze the role of VWF in the function of the contact pathway, the

polymerization of fibrin was monitored on the surface of VWF fibers created under different
conditions. To isolate the role of VWF from the effect of platelets, platelet-free plasma
(PFP) was used for both fibrous VWF formation and the subsequent coagulating flow over
the VWF. When Factor XIIa was only weakly inhibited with 4 μg/mL CTI in recalcified
citrated PFP that was perfused over VWF fibers previously made in the presence of EDTA,
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fibrin began polymerizing on the surface of the VWF fibers within 7 min at an upstream
wall shear rate of 1500 s-1 (Figure 3-4A).
However, it was unclear whether: (case 1) the VWF fibers themselves were
initiating the contact pathway as a surface activator of Factor XII, (case 2) the VWF fibers
had accumulated contact pathway factors as they formed (EDTA does not inhibit FXIIa
generation or thrombin activity), or (case 3) fibrin fibers were forming upstream in the
device in low CTI plasma and were simply accumulating on the VWF. Surface-adsorbed
VWF did not initiate significant contact activation in a well plate thrombin assay (Figure
3-5). When the low CTI-plasma perfusion experiment was repeated with an empty post,
no fibrin was formed or captured (Figure 3-4B). Similarly, when repeating the experiment
with micropost-captured fibrillar collagen in place of the VWF fibers, no fibrin formed on or
was captured by the collagen fibers (equine fibrillary collagen type 1, Chronopar,
Chronolog) (Figure 3-4C). The shear rate of 1500 s-1 was too low for the plasma VWF to
form massive VWF fibers on the collagen. These two results demonstrated that fibrin
polymerization occurred on the VWF fibers in Figure 3-4A conditions and was not simply
forming upstream and capturing on the post or fibers (case 3). To distinguish case 1 (FXIIa
generation) from case 2 (contact factor accumulation) the previous experiment was
repeated with VWF fibers generated from fully inhibited plasma (apixaban/PPACK/highCTI/EDTA). By inhibiting these active factors during VWF fiber multimerization, FXIIa
activation and subsequent thrombin and fibrin generation would need to initiate on that
VWF surface during perfusion of low CTI plasma. However, no fibrin formed on the fully
inhibited fibers (Figure 3-4D), eliminating case 1 and demonstrating case 2 where active
coagulation factors in low CTI plasma were concentrated in the VWF fiber as it formed.
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No extrinsic pathway participation of tissue factor or FVIIa function on platelets can occur
in these conditions [64].
To further investigate the possibility of upstream fibrin formation, we measured
thrombin activity in calcium-containing plasma formed in the well prior to entrance into the
microfluidic channel. Using the fluorogenic thrombin substrate boc-VPR-MCA, CTI-treated
recalcified citrated plasma did not generate any detectable thrombin in 20 min. With no
thrombin present in the upstream reservoir under the conditions of the experiment, fibrin
would not be able to polymerize upstream. We conclude that fibrin was generated on the
VWF itself from local thrombin within the VWF, rather than deposition of fibrin formed
upstream.
Additionally, VWF fibers were formed at pathological shear from EDTA-treated
normal plasma or FXII-deficient plasma and then immunostained with fluorescent antiFXII(a) in HBS. FXII(a) immunofluorescence was detected on VWF fibers from EDTAplasma, but not on FXII-deficient plasma (Figure 3-6). When FXIa generation was inhibited
by 14E11 antibody (an antibody that binds FXI and prevents its activation by FXIIa) in the
plasma used to generate VWF, no fibrin formed subsequently on the deposited VWF fibers
when recalcified plasma was perfused (Figure 3-7). This experiment demonstrated that
FXIa (and its co-localized activator, FXIIa as seen in Figure 3-6) were localized on the
VWF during fiber formation under pathological flow.
A “bystander effect” was observed when fibrin was allowed to form on the VWF
before perfusion of tPA. Though tPA was not able to convert plasminogen to plasmin on
the surface of VWF fibers, plasmin generated by tPA on the surface of fibrin (co-localized
with the VWF fiber) was able to cleave nearby VWF (Figure 3-8).
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Figure 3-3: Sensitivity of VWF fibers to various proteases and surfactants
(A) VWF fibers were generated using EDTA inhibited PFP at 10000 s-1 for 5 min from initial
fiber capture. VWF was then labeled using polyclonal fluorescent anti-VWF antibody in
HBS, and then washed with HBS for 2 min to reduce background. When 0.25% trypsin
solution was perfused over the VWF at 10000 s-1, the fibers were digested in 10 s. (B)
When 2% SDS solution was perfused over the VWF at 10000 s-1, the fibers were dissolved
in 80 s. (C) VWF fibers were generated using apixaban and PPACK inhibited PFP at
10000 s-1 for 5 min from initial fiber capture. VWF was then labeled using polyclonal
fluorescent anti-VWF antibody in HBS, and then washed with HBS for 2 min to reduce
background. The shear rate was reduced to 1500 s-1 and apixaban and PPACK inhibited
PFP with 50 nM ADAMTS13 was perfused over the fibrous VWF for 480 s. (D) VWF fibers
were generated in the same way as C. The shear rate was reduced to 1500 s-1 and
apixaban and PPACK inhibited PFP with 100 nM tPA was perfused over the fibrous VWF
for 300 s. (E) VWF fibers were generated in the same way as A. When 1 μM plasmin in
HBS was perfused over the VWF fibers at 1500 s-1, the fibers were digested in 40 s.
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Figure 3-4: Fibrous VWF provides a surface for coagulation via contact pathway
(A) VWF fibers were generated using EDTA PFP at 10000 s-1 for 5 min from initial fiber
capture. VWF was then labeled using polyclonal fluorescent anti-VWF antibody in HBS,
and then washed with HBS for 2 min to reduce background. The shear rate was reduced
to 1500 s-1 and recalcified low CTI (4 μg/mL, LCTI) citrated PFP labeled with fluorescent
anti-fibrin antibody was perfused over the fibrous VWF for 20 min. (B) No VWF fibers were
generated on the post before perfusion of recalcified LCTI citrated PFP labeled with
fluorescent anti-fibrin antibody at 1500 s-1 for 20 min. No fibrin formed on the post. (C) 10
μg/mL collagen type 1 solution in HBS was perfused over the post for at 10000 s-1 until
the collagen fibers were approximately the same size as the previous VWF fibers.
Recalcified LCTI citrated PFP labeled with fluorescent anti-fibrin antibody was then
perfused over the collagen fibers at 1500 s-1 for 20 min. No fibrin formed on the collagen
or post. (D) VWF fibers were generated using 40 μg/mL CTI, 1 μM apixaban, 100 μM
PPACK, and 5 mM EDTA inhibited PFP at 10000 s-1 for 5 min from initial fiber capture.
VWF was then labeled using polyclonal fluorescent anti-VWF antibody in HBS, and then
washed with HBS for 2 min to reduce background. The shear rate was reduced to 1500 s1
and recalcified LCTI citrated PFP labeled with fluorescent anti-fibrin antibody was
perfused over the fibrous VWF for 20 min. No fibrin formed on the inhibited VWF fibers.
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Figure 3-5: Sorbed VWF does not initiate thrombin generation through the contact
activation pathway
Recombinant VWF (100 μg/mL), 5% BSA, or HBS incubated in a 384 well plate for 4 hours
to allow for protein adsorption. These surfaces were then washed with PPACK and
apixaban in HBS, followed by an HBS wash. Calcium buffer (15 mM final concentration)
with Boc-VPR-MCA was added to each well as a fluorescent thrombin substrate, and
kaolin was added to the sorbed HBS well as a known potent contact pathway activator.
PFP inhibited with 4 μg/mL CTI and citrate was then added to each well and mixed.
Substrate fluorescence was measured by a plate reader (Fluoroskan) every 15 seconds.
Average fluorescent intensity and standard deviation was calculated (n=5).
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Figure 3-6: FXII(a) localized on fibers
VWF fibers were formed at pathological shear from EDTA-treated plasma or FXII-deficient
plasma and immunostained with anti- αFXII(a). VWF fibers formed from normal plasma
displayed FXII(a) immunostaining. No staining was detected on VWF fibers formed from
FXII-deficient plasma.
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Figure 3-7: Fibrin formation on VWF fibers was blocked by anti-FXI antibody (14E11)
which had been present during VWF fiber formation
The 14E11 antibody, which blocks FXIa formation by FXIIa, was added to EDTA plasma
during VWF fiber generation, followed by perfusion of low CTI, recalcified plasma (lacking
14E11) over the fibers. No fibrin formed after 20 min perfusion, demonstrating that FXIa
was deposited on the VWF fibers as they were generated.

45

Figure 3-8: Bystander effect allowed fibrin/tPA-dependent generation of plasmin
which then led to subsequent solubilization of VWF fibers
Low CTI recalcified PFP was perfused over VWF fibers made with EDTA PFP. After fibrin
had formed on the VWF fibers, 100 nM tPA was added to low CTI recalcified PFP and
perfused over the fibrin and VWF. Both the fibrin and VWF were cleaved by 150 s.
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3.3.4

Platelets roll and adhere on VWF fibers but pathological shear drives Pselectin display
Whole blood anticoagulated with PPACK/apixaban and treated with fluorescent

anti-CD41

and

anti-CD62P

was

perfused

over

fibrous

VWF

(formed

from

PPACK/apixaban-treated plasma) at 1500 and 3000 s-1. Platelets attached, rolled, and
firmly bound to the fibrous VWF at both shear rates (Figure 3-9), demonstrating the
previously observed behaviors seen on endothelial anchored VWF [65], immobilized
plasma VWF [66,67] and fibrous VWF on collagen [38]. Additionally, platelets arrested on
the fibrous VWF at either shear rate, but only displayed P-selectin at 3000 s-1 (Figure
3-9A), consistent with a role for fibrous VWF supporting shear-induced platelet activation
(SIPA). The wall shear rates seen on the surface of fibers (~5000 s-1) were obtained with
an upstream approach wall shear rate of 1500 s-1 (Figure 3-10). GR144053 at 2 μM to
inhibit IIb 3 prevented platelet arrest on the VWF fibers (Figure 3-9B). Therefore, fibrous
VWF was a platelet activating surface under physiological arterial shear rates and a
cofactor for SIPA at pathological shear rates to induce P-selectin display.
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Figure 3-9: Platelets adhere to and activate on fibrous VWF
(A) VWF fibers were generated using apixaban and PPACK inhibited PFP at 10000 s-1 for
5 min from initial fiber capture. VWF was then labeled using polyclonal fluorescent antiVWF antibody in HBS, and then washed with HBS for 2 min to reduce background. The
shear rate was reduced to either 1500 s-1 or 3000 s-1 and apixaban and PPACK inhibited
whole blood labeled with fluorescent anti-CD41 (platelets) and fluorescent anti-CD62P (Pselectin) was perfused over the fibrous VWF for 10 min. (B) VWF fibers were generated
and labeled using the same procedure as A. The addition of GR 144053 to the whole
blood described in A resulted in total inhibition of firm platelet adhesion to the VWF fibers.
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Figure 3-10: Local shear stress on surface of fibrous VWF does not predict location
of activated platelets
The fluorescent signal from the VWF from Figure 3-9 was traced and modeled in COMSOL
to approximate the three-dimensional structure of VWF in the device. Device shear was
set to 1500 s-1 to simulate the conditions for the platelet activation experiments to
determine the shears experienced by platelets at positions along the surface of VWF.
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Figure 3-11: Chelation of calcium and inhibition of calcium-dependent ADAMTS13
activity in plasma does not result in a significant differences in fiber size
Apixaban/PPACK plasma with or without EDTA was used to form VWF fibers at a shear
rate of 10000 s-1. Since ADAMTS13 requires calcium, we found no significant influence of
ADAMTS13 in VWF fiber formation, an expected result since plasma ADAMTS13 had
already processed the soluble VWF multimers in the plasma used to form the fibers.
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3.4

Discussion
By designing a microfluidic device capable of capturing multimerized VWF fibers in

pathological shear flow, we were able to investigate mechanical, biochemical, and
biological properties of fibrous VWF. The lack of collagen in the VWF capture method of
this device allows the role of VWF to be examined without collagen present, and may be
more representative of the VWF-rich regions of thrombotic clots seen in the work of Le
Behot et al. [7], where VWF incorporated into the top region of nearly occlusive thrombi
and was not directly bound to subsurface collagen [7]. The determination of the VWF fiber
elastic modulus is potentially quite useful for whole clot mechanical modeling, particularly
in studying thromboembolism [68,69]. Another advantage to this approach is that the VWF
fibers are formed under single-pass shear flow, which is a more physiologically relevant
condition than continuous exposure in a cone and plate viscometer or vortexing assays
[70,71]. VWF aggregates produced in a cone and plate viscometer have previously been
shown to partially dissociate after treatment by SDS [72], but we have shown that fibrous
VWF made under elongational flow also dissociates in response to SDS. This single-pass
flow approach demonstrates that the sensitivity of VWF fibers to trypsin, SDS, and plasmin
does not require long incubation times to achieve substantial degradation of the fibers.
The focus of this study is on human plasma VWF, which unlike VWF secreted by
endothelial cells, is made up of subunit fragments resulting from processing of endothelial
VWF by ADAMTS13 [73,74]. For endothelial released ultra-large VWF, cleavage by
ADAMTS13 regulates the release and size of VWF multimers by cleaving the A2 domain
of VWF to release it into the blood stream [74]. As a result, the fibers observed in this
study, and potentially those in the high shear exposed regions of large thrombi, would
potentially have resistance to ADAMTS13 due to a lower fraction of structurally exposed
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A2 domains for cleavage of large VWF fibers. The ADAMTS13 sensitivity of VWF fibers
in the absence of platelets has not been previously studied [75]. Although soluble VWF
multimers have been shown to reduce in size in the presence of ADAMTS13 and shear
[76], the ability of ADAMTS13 to cleave insoluble VWF fibers was observed in this assay
to be undetectable. The effect of calcium, and therefore endogenous calcium-dependent
ADAMTS13 activity, on the formation size of VWF fibers was found to be insignificant
(Figure 3-11), consistent with the fact that the plasma VWF multimers incorporated into
the fiber at pathological shear rate were already processed by ADAMTS13. Distinct from
observations of acutely released ULVWF from stimulated endothelium, the massive VWF
fibers formed at high shear from processed plasma VWF were insensitive to ADAMTS13.
In typical thrombolytic therapy, tPA is used to dissolve fibrin rich thrombi by
converting plasminogen into plasmin on the surface of fibrin, which then degrades fibrin
[77]. In occlusive thrombi, degradation of clot-integrated VWF by plasmin could synergize
with the cleavage of fibrin to contribute to overall thrombolysis. Both trypsin and plasmin
can reduce the average multimer size of purified soluble VWF [63]. We show these
activities are maintained on the insoluble fibrous form of VWF generated from plasma.
However, fibrous VWF was not a cofactor for tPA. The resolution of VWF in an arterial
occlusion during thrombolytic therapy with tPA would require the transfer of plasmin from
degrading fibrin to the fibrous VWF without inhibition by soluble or fibrin-linked antiplasmin.
Coagulation on the surface of fibrous VWF could play an important role in
propagating clot growth to occlusion in severe thrombosis. The role of the contact pathway
in arterial thrombosis has received considerable attention recently [12–14]. Because
collagen and apixaban/PPACK/high-CTI/EDTA inhibited VWF fibers do not lead to fibrin
formation, we conclude that active FXIIa or FXIa accumulated on VWF fibers while they
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formed. Endothelial cell-anchored ultra-large VWF has been shown to cause localization
of other blood proteins on VWF [78]. Coagulation factor accumulation could potentially
lead to a second wave of coagulation at the top region of a thrombus, leading to vessel
occlusion.
Though it is well established that platelets bind to and roll along endothelial bound
multimeric VWF [65], it had not previously been observed on multimeric plasma VWF in
the absence of collagen as a confounding platelet stimulus [38]. Rolling adhesion occurs
through GPIbα, and firm adhesion occurs through IIb3, but platelet activation that occurs
when bound to VWF is thought to do so through GPIb caused by GPIb clustering on
the surface of platelets [79]. The resulting proximity to the VWF fibers allows the slower
but long-lived IIb 3 bond to take stably take hold of the platelet. Outside-in signaling via
GPIb or αIIbβ3 could also contribute to platelet activation through a mechano-sensitive
mechanism when bound to VWF [80]. Only if prevailing shear rates are pathological can
the shear forces on the platelet drive P-selectin exposure (Figure 3-9). In summary, we
report that fibrous VWF formed under conditions of pathological stenotic flow are nonamyloid, plasmin sensitive but tPA-resistant, procoagulant through accumulation of
contact pathway factors, and substrates for SIPA at pathological shear rates.
3.5

Summary
Under severe stenotic conditions, von Willebrand Factor (VWF) multimerizes into

large insoluble fibers at pathological shear rates. Our objective was to evaluate the
mechanics and biology of VWF fibers without the confounding effects of endothelium or
collagen. Within a micropost-impingement microfluidic device, >100 m long VWF fibers
multimerized on the post within 10 min using EDTA-treated PFP perfused at wall shear
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rates >5000 s-1. VWF fiber thickness increased to >10 m by increasing shear rate to
10,000 s-1. In a stress-strain test, fibrous VWF had an elastic modulus of ~50 MPa. The
insoluble VWF fibers were non-amyloid since they rapidly dissolved in trypsin, plasmin, or
2% SDS, but were resistant to 50 nM ADAMTS13 or 100 nM tPA in plasma. Following
fiber formation, perfusion of low corn trypsin inhibitor (CTI)-treated (4 g/ml), recalcified
citrated plasma at 1500 s-1 caused fibrin formation on the VWF fibers, a result not observed
with purified type 1 collagen or a naked micropost. During VWF fiber formation, contact
pathway factors accumulated on VWF since the use of EDTA/PPACK/apixaban/high CTItreated PFP during VWF fiber formation prevented subsequent fibrin production from low
CTI, recalcified citrated PFP. When PPACK-inhibited whole blood was perfused over VWF
fibers, platelets rolled and arrested on the surface of VWF, but only displayed P-selectin
if prevailing shear rates were pathological. Platelet arrest on VWF fibers was blocked with
IIb3 antagonist GR144053. These observations reveal VWF fiber-contact pathway
crosstalk and new mechanisms of thrombolytic resistance in the hemodynamic setting of
acute myocardial infarction.
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CHAPTER 4: THROMBI PRODUCED IN STAGNATION POINT FLOWS HAVE A
CORE-SHELL STRUCTURE
4.1

Introduction
Platelet response at sites of vascular injury is crucial for hemostasis. However,

excessive platelet aggregation and thrombin generation at sites of atherosclerotic plaque
rupture can lead to occlusive thrombi that drive acute coronary syndromes. In regions
where vessel geometry gives rise to flow recirculation and stagnation point flows, the risk
of endothelial dysfunction and thrombosis may be enhanced. Stagnation point flows occur
at several locations of diseased vasculature, including in vessel bifurcations and at
reattachment points downstream of stenotic geometries [81]. Thrombosis at stagnation
points have been observed in a number of vessel geometries, particularly in preferred
sites of atherosclerotic lesions, including parts of the aorta [82] and carotid-posterior
communicating artery junction [83]. Because this unique flow pattern results in unusual
platelet and agonist transport and fluid forces compared to typical vessel flow, it is
important to understand how these factors affect clot growth and structure.
Stagnation point flow has been shown to alter endothelial cell biology, shape, and
density. Human atherosclerosis develops preferentially in low shear stress, oscillatory,
and reversing flow regions of arteries, including adjacent to stagnation points, where lipids
tend to deposit in the arterial wall [84]. Endothelial cells in these regions also tend to be
less densely packed and less aligned compared to the high density and elongated
endothelial cells found in regions of high and unidirectional wall shear stress, as seen both
in in vitro disturbed flow assays and in vivo atherosclerotic studies [85,86]. These
conditions lead to the development and worsening of plaques in humans [86].
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In these regions, any gap in the endothelium or plaque rupture can expose a
thrombogenic surface to the blood. Since blood flow at the stagnation point is zero, there
is potentially a longer residence time for platelets to bind to any exposed collagen, as well
as decreased convective transport of agonists leading to more activated platelets near
stagnation points.
Previously, stagnation point thrombosis has been examined primarily using radial
flow geometries on either synthetic or cell surfaces. Petschek and colleagues [87]
examined the formation of platelet clots from canine blood on glass and polyurethane
surfaces in a stagnation point geometry with radial flow. Reininger and colleagues [88]
examined radial stagnation point flows of platelet-rich plasma on intact endothelial cells,
and found that adhesion only occurred when platelets were pre-stimulated with ADP.
David et al. [89] developed a mathematical and numerical model for the adhesion of
platelets in stagnation point flow using a shear dependent reaction rate, and found that
the maximum platelet flux occurs downstream of the stagnation point, rather than at it. In
these previous experimental studies, a radially-directed and decelerating flow developed
from the stagnation point. In these geometries, flow velocity drastically decreases as it
moves radially. However, this radial flow is unlike the flow field expected at the
reattachment point distal to a stenosis.
In this study, a stagnation point microfluidic device was developed with the ability to
localize collagen and TF to a scaffold region, which was then subject to a perpendicular
flow of whole blood impinging on the thrombotic collagen/TF surface. We demonstrate the
ability to initiate and grow thrombi at a stagnation point using human whole blood and
examine their structures under different flow and biochemical conditions.
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4.2
4.2.1

Materials and Methods
Blood collection and preparation
Human blood was obtained from healthy donors who self-reported as free of any

bleeding diseases or disorders, as well as free of oral medication for at least 10 days. All
blood was collected in accordance with the University of Pennsylvania’s Internal Review
Board. Blood was anticoagulated with 40 μg/mL corn trypsin inhibitor (CTI, Haematologic
Technologies Inc., Essex Junction, VT) to inhibit factor βXIIa. Depending on the
experiment, PE-labeled anti-CD61 and anti-CD62P (BD Biosciences, San Diego, CA,
USA) were used to label platelets and P-selectin, respectively. FITC-conjugated anti-von
Willebrand Factor antibody (Abcam, Cambridge, MA, USA) was used to label von
Willebrand Factor (VWF), and anti-fibrin antibody (gift from M. Poncz, Children’s Hospital
of Philadelphia) was used to label fibrin. N-acetylcysteine (NAC, Sigma Aldrich) and antiCD42B (anti-GPIb antibody, Abcam) were also added to whole blood before perfusion in
certain experiments, where indicated.
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Figure 4-1: Microfluidic device design and characterization
(A) The stagnation point device contained 3 ports for loading collagen into the scaffold
region, and 3 ports for controlling blood flow. (B) At the region of interest, the inlet blood
flow impinged on a collagen scaffold surface on the side wall before diverging to the blood
outlets. All channels were 250 μm wide and 60 μm deep. Posts within the scaffold region
were 50 μm in diameter. (C) COMSOL-simulated streamlines depict impinging flow at the
stagnation point at the center of the collagen scaffold.

58

4.2.2

Microfluidic device design and fabrication
Microfluidic devices were fabricated out of polydimethylsiloxane (PDMS, Ellsworth

Adhesives, Germantown, WI, USA) using previously described soft lithography techniques
[44,58,59]. The stagnation point device (Figure 4-1A) consisted of two perpendicular
channels with 250 μm width and 60 μm height that intersect at the scaffold region (Figure
4-1B). Collagen inlets (labeled Ci) were positioned on either side of the blood inlet channel
(labeled Bi), and the collagen outlet used to pull collagen into the scaffold region (labeled
Co) was located behind the scaffold posts. The scaffold was designed with post array (Dpost
= 50 μm) spaced 20 μm apart with an opening narrowing from L = 250 μm at the channel
interface to L = 50 μm at the outlet (Figure 4-1B). The posts positions were optimized for
uniformly loading collagen fibers. [46]
4.2.3

Computational fluid dynamics
Finite element simulations were conducted using COMSOL Multiphysics

(Burlington, MA, USA) to predict the blood flow profile and shear rates with and without
clot formation on the collagen/TF surface at inlet flow rates of 10 and 100 μL/min. The
model shown (Figure 4-2) was not dependent on hematocrit and was a computational fluid
dynamics model using a constant blood fluid density of 1060 kg/m3 and a Newtonian blood
viscosity of 3.39 cP [60]. The collagen/TF surface was approximated as an impermeable
wall such that all fluid impinging on the collagen/TF surface exited the device via the two
blood outlets (Figure 4-1B).
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4.2.4

Microfluidic flow experiments
Devices were secured to the surface of Sigmacote® (Sigma-Aldrich, St. Louis, MO,

USA)-treated glass slides using a vacuum pump, and the channels were coated with 10%
bovine serum albumin (BSA) for 30 minutes. Polymerized fibrillar collagen was prepared
by incubating collagen (3 mg/mL monomeric human type I, Vitrocol, Advanced BioMatrix,
Inc., Carlsbad, CA, USA), 10X PBS, and 90 mM NaOH in an 8:1:1 ratio at 37°C overnight.
Lipidated tissue factor (Dade® Innovin® recombinant human TF, VWR Corp, Radnor, PA)
was prepared as previously described [90] and mixed with the polymerized collagen in a
1:20 ratio by volume. The solution was incubated for 10 minutes at room temperature. To
load collagen into the device scaffold, 2 μL of the collagen solutions were pulled into the
scaffold via the two “collagen in” ports (Figure 4-1A). 5 mM Ca2+ buffer was then rinsed
through the channels to remove any collagen outside of the scaffold region. The final
tissue factor surface concentration was ~1 molecule/μm2. The collagen in and out ports
were plugged to prevent additional flow during blood perfusion. The blood flow was
controlled via syringe pump (Harvard Apparatus, Holliston, MA, USA) connected to the
two “blood out” ports to withdraw blood from the inlet port to the two outlet ports.
Microfluidic devices were mounted on an Olympus IX81 inverted microscope (Olympus
America, Center Valley, PA, USA) equipped with a charge-coupled device camera
(Hamamatsu, Bridgewater, NJ, USA). Thrombus growth was quantified by measuring the
clot height at 10 evenly spaced positions across the collagen/TF surface at each time
point. Average clot height and standard deviation were calculated for each condition and
time point across multiple replicates.
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4.3
4.3.1

Results
Microfluidic device produces stagnation point flows with controllable shear
gradients
A microfluidic device was designed to create a flow pattern that produced a

stagnation point on a collagen/TF surface, while fluorescently imaging local clot formation
at and near the stagnation point. By designing the device to have the collagen surface on
a side-wall, it enabled direct monitoring of the clot growth along the growth axis as well as
morphological differences along the clot height. After collagen/TF was loaded into the
device (Figure 4-2A), the collagen inlets and outlets were plugged and the flow path
consisted solely of the blood inlet channel and the two blood outlet channels. Initially, the
calculated wall shear rate is zero at the impingement point and increases monotonically
to the outlet shear rate far from the stagnation point for 3 different inlet flow rates of 10,
50, and 100 μL/min (Figure 4-2B). Over the collagen/TF region, the shear rate increases
outward from the stagnation point in a roughly linear gradient that significantly increases
as flow rate increases (∇γw = 1.2 s-1/μm at 10 μL/min and 12.5 s-1/μm for 100 μL/min). This
setup allows for the examination of both low shear gradients (10 µL/min) and high shear
gradients (100 µL/min) over the same thrombotic zone in this flow geometry. The inlet flow
rates of 10 and 100 μL/min resulted in inlet channel shear rates of 100 s-1 and 1000 s-1,
respectively.
As a thrombus grows on the collagen/TF surface, the local wall shear rate profile
will change due to differing local fluid velocities. To simulate this, a 50-µm high rounded
thrombus was added over the thrombotic surface (Figure 4-2C). This change in flow
geometry had two effects on the wall shear rates (Figure 4-2D). First, the shear gradients
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Figure 4-2: Simulated wall shear rate profiles evolve during clot growth
(A, B) Prior to clot formation, the wall shear rate increased approximately linearly
throughout the collagen region before plateauing at a final shear rate in both side
channels. Higher inlet flow rates led to steeper wall shear rate gradients over the collagen
surface. (C, D) As the clot grew, the shear gradients surrounding the stagnation point
steepened in the collagen region. The final wall shear rates in the side channels remained
the same.
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immediately surrounding the stagnation point steepened. Second, the monotonic behavior
of the shear rate disappeared as flow both accelerated and decelerated near the surface
of the thrombus due to the influence of the constraining microfluidic boundaries. Even
within the small area around a stagnation point, regions of both high and low shear
rates/gradients as clots grow were observed in the simulation.
4.3.2

Stagnation point thrombi display a core-shell architecture
Whole blood anticoagulated with CTI and treated with fluorescent anti-CD61, anti-

CD62P, and anti-fibrin (labeling platelets, P-selectin, and fibrin, respectively) was perfused
through the device at 10 or 100 µL/min impinging upon the collagen/TF surface, where it
was allowed to clot for 8 minutes (Figure 4-3). Platelets immediately began binding to the
thrombotic surface on either side of the stagnation point, but did not adhere at the
stagnation point itself. This phenomenon, which has been previously observed in radial
flows [91], was potentially due to decreased platelet flux at in the centerline of the flow.
A difference in thrombus morphology was observed between the lower and higher
inlet flow rates. At the low flow rate, the thrombi were noticeably dendritic in structure, with
gaps between each deposit where platelets were not able to easily access. In contrast,
thrombi formed at the high flow rate were relatively uniform across the length of the
collagen. This difference was likely due to thrombus remodeling in response to
hemodynamic forces, where higher flow rates lead to strong shear gradients that deform
and densify the platelet masses, leading to a more evenly spread thrombus. It appears
that the dendritic structure of the thrombi results from buildup rather than embolization.
Because the thrombotic surface has some roughness, there is early roughness in the
location of platelet deposits which propagate as additional platelets
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Figure 4-3: Core-shell thrombus morphology observed at low and high shear rates
Perfusion of high CTI whole blood at an inlet flow rate of 10 μL/min on a collagen/TF
surface resulted in the formation of irregular heterogeneous platelet (green) clots.
Significant fibrin formation (red) and platelet activation (blue, observed via P-selectin
labeling) demonstrated a core-shell architecture as previously described [92]. At an inlet
flow rate of 100 μL/min, the same core-shell architecture was seen, but in a much denser
and regular clot shape.
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adhere to the deposits. Once they take on a dendritic structure, there is poor flow between
the dendrites, resulting in low platelet delivery in those gaps. After 8 minutes, clots formed
at 10 and 100 μL/min measured 44.9 μm and 37.6 μm in average height above the
collagen/TF surface, respectively.
The clots formed at both low and high flow rates display a distinct core-shell
architecture that has been extensively described in multiple in vitro and in vivo studies
[92,93]. It is interesting that although the flow direction with respect to the clots is different,
the pattern of a highly activated (P-selectin-positive) and fibrin rich core surrounded by a
P-selectin-negative, less dense platelet shell was still maintained. Thrombin generation
and fibrin at the collagen/TF surface colocalized with the majority of the platelet activation
in the core of these clots.
4.3.3

N-acetylcysteine reduces platelet deposition near stagnation points
To analyze the role of VWF in thrombus formation in this geometry, CTI whole

blood labeled with fluorescent anti-CD61 and anti-VWF was perfused over a collagen/TF
surface at 10 and 100 µL/min (Figure 4-4). At both flow rates, VWF firmly adhered to the
collagen surface, but was also found throughout the platelet structure. Some incorporation
of VWF onto the collagen surface was expected, even at lower shear rates [94].
Previously, it has been shown that NAC promotes disaggregation of arterial
thrombi by interfering with the platelet/VWF interactions and interfering with disulfide
bonds inside multimeric VWF [4,7]. To investigate if NAC had a similar effect during the
formation of stagnation point thrombi, the assay was repeated with a high dose of NAC.
When 30 mM NAC was added to the whole blood before perfusion, platelet adhesion was
drastically reduced in the low flow rate condition, and was eliminated in
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Figure 4-4: NAC reduced the height of stagnation point clots
High CTI whole blood was perfused over collagen/TF surfaces at an inlet flow rate of 10
μL/min or 100 μL/min with or without 30 mM NAC. Clots formed with NAC were smaller
and contained less VWF than the control clots.
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the high flow rate condition. Despite the much smaller thrombus in the low flow rate
condition, the platelets still co-localize with VWF, but the amount of VWF overall was
decreased from the control condition without NAC.
4.3.4

Polymerized fibrin was not required for clot stability
In clot formation under unidirectional flow, fibrin plays an important role in clot

stability and in preventing embolization [58]. To examine the role of fibrin in the stagnation
point geometry, the peptide Gly-Pro-Arg-Pro (GPRP) was used to inhibit the
polymerization of fibrin monomers into fibrin polymer. Whole blood anticoagulated with
CTI was incubated with and without 1 mM GPRP prior to perfusion at 10 and 100 μL/min
over a collagen/TF surface (Figure 4-5). When fibrin polymerization was inhibited, the
overall structure of the platelet mass and VWF accumulation appeared similar to that seen
with fibrin present.
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Figure 4-5: Polymerized fibrin was not required for stagnation point clot stability
High CTI whole blood was perfused over collagen/TF surfaces at an inlet flow rate of 10
μL/min or 100 μL/min with or without 1 mM GPRP, which inhibited fibrin polymerization.
The absence of polymerized fibrin did not lead to clot instability.
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4.4

Discussion
The development of in vitro microfluidic assays have been useful in probing the

mechanisms by which clots grow under flow [46,48]. In this study, we were able to examine
the clot morphology resulting from pathologically relevant flows by designing a microfluidic
device capable of generating stagnation point flows on a thrombotic collagen/TF surface.
One advantage to this device is the creation of an essentially two-dimensional stagnation
flow, which more closely recapitulates the flow and transport found around stagnation
points in stenosed blood vessels compared to the radial flow stagnation points deployed
in previous studies. This study was the first to observe that clots formed at/near stagnation
point flows adopt a core-shell architecture, just like those observed previously in parallel
flows both in microfluidic studies [46] and mouse studies [95].
Another advantage over previous stagnation studies is the side-view orientation of
this microfluidic device, which enables direct observation of clot growth and the ability to
see spatial differences along the growth axis in qualities such as P-selectin activation,
fibrin generation, or VWF incorporation. This fact allows the in vitro thrombi grown in this
device to be compared to in vivo intravital mouse imaging, future comparisons between
the well-controlled flow and whole blood conditions in vitro to the more complex and
physiological in vivo environment and geometry.
The addition of NAC into the system had a pronounced effect on platelet deposition
around the stagnation point. At low shear rates, NAC seemed to interfere with VWF-VWF
interactions, as observed in previous work [4], reducing the overall platelet deposition. At
high shear rates, however, NAC abolished platelet deposition on collagen/TF, suggesting
a role for VWF in the high shear environment around stagnation points. VWF observed in
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the platelet mass itself could be both plasma and/or platelet derived. The VWF closer to
the top of the clot was likely to be plasma VWF due to the increased shear gradients on
the surface of the clot as it grows, but also because the platelets in the top of the clot (the
shell) were P-selectin-negative, suggesting the platelet VWF was probably not present in
the shell. However, the large amount of VWF present at the base of the clots for both flow
rates suggested that there may be a combination of plasma and platelet VWF in the core
as both high shear gradients and platelet activation were present. In future work, an
examination of the colocation of P-selectin exposure and VWF in the core and the shell
could provide interesting insights about the origins of the clot-incorporated VWF.
Further study into mechanisms of VWF involvement could be conducted with von
Willebrand disease patient whole blood to see if the absence or dysfunction of VWF
eliminates stagnation point clots. Although this model does not imitate the moving
stagnation points found in some vessel geometries due to pulsatile flows with a
recirculation eddy, this device has allowed for the study of thrombus formation in steady
flow conditions. This device may be suited for studying clotting in pulsatile inlet flow
conditions where the stagnation point doesn’t move. Additionally, a more detailed
calculation of the cell-free layer and hematocrit could be achieved using a particle
suspension model [96] to further improve the computational fluid dynamics model.
The effect of GPRP on thrombus structure in this geometry was not initially
expected, since fibrin is thought to be important in the stability of thrombi formed in parallel
flow. The unique flow situation of stagnation point flow seem to play an important role in
clot stability by providing perpendicular fluid forces keeping the thrombus more securely
held to the collagen/TF surface. As the thrombus grows further away from the stagnation
point, where the flow conditions become more like parallel flow, it is expected that the clot
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stability would again become dependent on fibrin. Additional studies examining the effect
of tissue plasminogen activator on thrombus stability may provide additional evidence in
understanding the role of fibrin in stagnation point thrombi.
In summary, we report a model for the study of thrombus formation around
stagnation points to probe clot structure and help to elucidate the mechanisms involved.
4.5

Summary
In regions of flow separation/reattachment within diseased arteries, the local

hemodynamics can result in stagnation point flow that provides an atypical environment
in atherosclerosis. Impinging flows occur with recirculation eddies distal of coronary
stenosis or diseased carotid bifurcations. By perfusing whole blood directly perpendicular
to a fibrillar collagen thrombotic surface, a microfluidic device produced a stagnation point
flow. Side view visualization of thrombosis in this assay allowed for observation of clot
structure and composition at various flow rates and blood biochemistry conditions. For
clotting over collagen/tissue factor surfaces, platelet thrombi formed in this device
displayed a core-shell architecture with a fibrin-rich, platelet P-selectin-positive core and
an outer platelet P-selectin-negative shell. VWF was detected in clots at low and high
shear, but when N-acetylcysteine was added to the whole blood, both platelet and VWF
deposition were markedly decreased at either low or high flow. To further examine the
source of clot stability, 1 mM GPRP was added to prevent fibrin formation while allowing
the PAR1/4-cleaving activity of thrombin to progress. The inhibition of fibrin polymerization
did not change the overall structure of the clots, demonstrating the stability of these clots
without fibrin. Impinging flow microfluidics generate thrombi with a core-shell structure.
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CHAPTER 5: OTHER STUDIES
5.1
5.1.1

Shear-Induced Platelet Activation
Introduction
Platelet activation under high shear conditions is a poorly understood process.

Mechanistically, shear-induced platelet activation (SIPA) involves the shear-mediated
binding of VWF to GPIb on the platelet membrane. The binding event provides outside-in
signaling that increases intracellular calcium and activates GPIIb/IIIa, which allows the
platelet to stably bind to VWF. The increase in intracellular calcium leads to overall platelet
activation, including granule release and P-selectin exposure. It is thought that SIPA may
play a role in the pathogenesis of diseases such as myocardial infarction [97] due to SIPA
observed in in vitro experiments. Because most shear-induced platelet activation studies
are conducted using a cone-plate viscometer [72,98], it isn’t possible to observe the
activation of a single platelet over time. Additionally, since platelets in a thrombus
experience shear from fluid flowing around them while they are held in place, these studies
do not replicate the in vivo flow conditions that cause platelets to activate in a thrombus.
5.1.2

Methods
The impingement-micropost device and a 60 μm-wide stenosis device were used

in conjunction to capture platelets on VWF from whole blood and to then observe platelet
activation in real-time. To analyze the localization of strain on the VWF fiber as it is
stretched by the increased flow rate, iterative particle image velocimetry (PIV) analysis
was used (ImageJ plugin PIV). This technique cross-correlated the position of regions on
the VWF fiber under increasing amounts of shear stress and used the integrated
displacement of each region along the fiber as an approximation for local strain. The
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stenosis microfluidic devices were placed over a patterned VWF strip adsorbed on the
glass slide to mimic non-stretchable VWF.
5.1.3

Results and Discussion
To get a better idea of the local strain environment of VWF fibers under shear flow,

particle image velocimetry (PIV) was conducted to analyze the relative displacements of
points on the fluorescently labeled VWF fiber as it stretched under step increases in shear
rate. Fluorescent images of VWF were processed using PIV, and the average cumulative
displacement of the VWF regions was found for both in the post region and the fiber region
(downstream of the post). VWF fibers within the fiber region experienced significantly more
stretching than the VWF in the post region, probably due to the friction between the VWF
and post (Figure 5-1). Because it has previously been observed that most of the activated
platelets on VWF are located in the fiber region [19], and the local wall shear rate on the
fiber is highest around the post, the increased strain could play a small role in activation
through mechanical stressing and outside-in signaling.
To examine this potential role, a comparison of platelet activation on a stretchable
VWF surface to a rigid VWF surface was examined. When PPACK/apixaban whole blood
(with labeled platelets and P-selectin) was perfused over VWF fibers formed from
PPACK/apixaban/citrated PFP at 1000 s-1 for 2 minutes, stable platelet adhesion along
the length of the VWF fiber was observed. The fluid was then switched to a buffer
containing anti-CD62P to visualize P-selectin activity. From this starting position, a
stepwise increase in shear rate (1000 s-1 every minute up to 12,000 s-1) resulted in
increasing platelet activation as measured by P-selectin fluorescent area per platelet area
(Figure 5-2A). When this whole blood perfusion and subsequent platelet exposure to shear
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was repeated over a strip of adsorbed recombinant VWF, platelets also firmly adhered
and activated in response to an increase in shear (Figure 5-2B). Because the P-selectin
per platelet area for both forms of VWF is similar at all tested shear rates, it is unlikely that
the stretching of fibrous VWF is significantly contributing to the activation of platelets via
pulling on αIIbβ3 on the platelets (Figure 5-2C). Because strongly activated platelets are
less likely to fall off of VWF due to high shear, it is observed that the proportion of activated
platelets increases over time on both forms of VWF (Figure 5-2D).
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Figure 5-1: Strain concentrates in the fiber region of VWF
VWF fibers labeled with a fluorescent antibody were stretched in a stepwise fashion from
1000 s-1 to 12,000 s-1 in 1000 s-1 steps every 60 seconds. The VWF fluorescent image
was analyzed using PIV plugin for ImageJ to cross-correlate the displacement of regions
on the VWF fiber. Cumulative strain (represented in heat map form) was approximated by
total displacement of the regions. VWF in the fiber region accumulated more strain than
the VWF in the post region.
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Figure 5-2: Platelets increasingly activate at higher shear rates on both fibrous and
patterned VWF
(A) Citrated PFP inhibited by PPACK and apixaban was perfused through the
impingement-micropost device at 10,000 s-1 to form VWF fibers. The shear rate was then
reduced to 1000 s-1 and the fibrous VWF was labeled using polyclonal fluorescent antiVWF antibody in HBS. After washing out with HBS to reduce background, PPACK- and
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apixaban-inhibited whole blood labeled with fluorescent anti-CD41 (platelets) and antiCD62P (P-selectin) was perfused over the VWF fibers for 2 min. After washing out the
whole blood in the channel with HBS, fluorescently labeled anti-CD62P labeled HBS was
perfused for 1 min at each 1000 s-1 step in shear rate, from 1000 s-1 to 12,000 s-1. (B)
Recombinant VWF was patterned on a glass slide using a microfluidic patterning device
previously described.[48] A 60 μm wide stenosis channel was placed over this VWF strip
perpendicularly to create a 60 μm x 100 μm patch of adsorbed VWF in the channel. The
same procedure from A was used for perfusion of whole blood and subsequent platelet
exposure to shear. (C) Platelets on both fibrous and patterned VWF increasingly activated
with increasing shear rate. There was no significant difference in platelet activation
between the stretching fibrous VWF and the non-stretching patterned VWF. (D) Both
forms of VWF experienced similar platelet loss as shear increased, contributing to the Pselectin/platelet increase with shear.
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5.2
5.2.1

Effect of N-Acetylcysteine on VWF aggregation
Introduction
VWF aggregation into fibers occurs in regions of high shear rate, such as in the

irregular flows of a vessel injury or on the top of a nearly-occlusive thrombus. This selfassociation of VWF from plasma is necessary for significant platelet recruitment in these
high shear areas. Because nearly-occlusive thrombi can lead to a number of conditions,
such as stroke, it is important to understand potential mechanisms for inhibiting VWF’s
role in the process.
N-acetylcysteine (NAC) is an FDA-approved antioxidant drug that is used for
treating acetaminophen overdose and for loosening thick mucus in patients with cystic
fibrosis or chronic obstructive pulmonary disease. In recent studies, it is thought to reduce
the size of soluble plasma VWF multimers and degrade ULVWF multimer strings released
from endothelial cells [99]. Stenosis-shaped microfluidic devices can be used to better
understand the potential use of NAC in treating thrombosis.
5.2.2

Methods
In this study, a protocol was developed to quantify the formation of VWF fibers on

a collagen surface at pathological shear rates. To do this, a 100 μm wide collagen strip
was applied to a glass slide using a microfluidic patterning device as previously described
[48]. A stenosis-shaped channel with a width of 15 μm was then placed perpendicularly
on top of the collagen, so that collagen was only exposed in the constant-width region of
the stenosis. Citrated PFP was then perfused through the device at 30,000 s-1 for 5 min,
resulting in VWF fiber deposition on the collagen. After washing out the plasma with 0.5%
BSA, labeling the VWF with fluorescent anti-VWF antibody, and then reducing the
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background with HBS, the now-fluorescent VWF fibers formed on the surface were able
to be visualized. Once fluorescent images were captured of the VWF fibers, ImageJ was
used to measure the length of and count each VWF fiber deposited in each channel, and
a histogram of all measured fiber sizes for each condition was created.
5.2.3

Results and Discussion
As a test of this protocol, a comparison of citrated PFP with or without NAC was

conducted. When 30 mM NAC was perfused over already formed VWF fibers, they did not
dissolve back into solution [19]. However, it has not previously been demonstrated
whether NAC might interfere with the action of plasma VWF aggregation. When 30 mM
NAC was added to citrated PFP and perfused over collagen at 30,000 s-1 for 5 min, fewer
and smaller VWF fibers formed on the collagen than in the HBS-treated control (Figure
5-3A), significantly for fibers 10-20 μm and 20-50 μm in length (Figure 5-3C). When
examining the histogram of fiber sizes, the addition of NAC resulted in a downward shift
in the size distribution of VWF fibers (Figure 5-3B). It was also observed that in the
presence of NAC, the total length of all fibers formed was less than half that of the control.
These results would suggest that NAC may play a role in inhibiting VWF aggregation into
fibers on the surface of collagen, opening the door for a potential application in inhibiting
high shear thrombosis.
A study by de Lizarrondo et al. [4] provides additional evidence suggesting the
NAC may be a safe alternative to antithrombotic agents in restoring vessel patency after
arterial occlusion. They demonstrate through a combination of in vivo and in vitro
experiments that intravenous NAC administration promotes the lysis of arterial thrombi
that are resistant to recombinant tPA, direct thrombin inhibitors, and antiplatelet
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treatments. They also provide evidence that NAC primarily targets the VWF that crosslinks
platelets in arterial thrombi, leading to disaggregation.
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Figure 5-3: N-acetylcysteine reduces VWF aggregation on collagen
(A) Citrated PFP with either 30 mM N-acetylcysteine (NAC) or HBS (control) was perfused
over a 100 μm wide collagen strip at 30,000 s 1 for 5 min. The channel was then washed
with 0.5% BSA, labeled with a polyclonal fluorescent anti-VWF antibody in HBS, and then
HBS to reduce background before imaging. (B) The length of each VWF fiber in each
image was measured, resulting in a size distribution of VWF fibers for both the control and
NAC conditions. (C) Inclusion of NAC in citrated plasma resulted in a lower number of
VWF fibers formed, and a significantly reduced number of 10-20 μm and 20-50 μm fibers
compared to the control [4].
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5.3
5.3.1

Role of GPVI in Trauma
Introduction
During trauma, major changes in blood biochemistry occur as a result of

hemorrhagic shock, endothelial release of tPA, release of tissue factor (TF) into the
vasculature, and systemic inflammatory events [100,101]. Since both thrombin and
plasmin are generated in the systemic circulation following trauma, elevated levels of
thrombin-antithrombin complexes and fibrin degradation products have been observed
[102–105]. Platelets obtained from trauma patients can display a hypofunctional
phenotype, despite baseline platelet counts and platelet P-selectin levels that are
comparable to healthy individuals [105].
Platelet GPVI is an immunoglobulin superfamily receptor present at about 4000
copies/platelet [106], corresponding to about 1 nM concentration in platelet rich plasma
(PRP). Although GPVI is thought to primarily bind to collagen during clot formation, recent
evidence has shown insoluble fibrin’s ability to both bind and agonise GPVI on platelets
within a forming clot [107,108]. However, the function of soluble fibrin species on platelets
in circulation (as in trauma) is not well understood. We hypothesized that platelet
hypofunction can result from low levels of soluble fibrin in circulation, and utilized the 8channel microfluidic device with exogenous soluble fibrin to test for any change in platelet
function on collagen [109].
5.3.2

Methods
Fluorescent fibrinogen (0.788 mg/mL) was incubated in either 5 mM GPRP or HBS

(control condition) for 10 min. Following incubation, 2.5 nM thrombin was added to each
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aliquot to generate either soluble fibrin monomer (GPRP present) or soluble fibrin polymer
(HBS control). After 300 seconds, thrombin activity was inhibited with 100 µM PPACK.
The resulting solutions were diluted by a factor of 10 in PPACK/apixaban-treated whole
blood (treated to prevent endogenous thrombin production or thrombin activity). Under the
conditions of this experiment, platelets in whole blood were not exposed to active
thrombin. In the 8-channel microfluidic device, platelet deposition from whole blood with
230 nM soluble fibrin monomer (GPRP condition) or 230 nM soluble fibrin polymer (HBS
control condition) was then tested for platelet deposition on collagen at a wall shear rate
of 200 s-1 (Figure 5-4A). The deposited platelet and fibrin fluorescence intensities were
recorded every minute for 6 minutes.
5.3.3

Results and Discussion
As expected, 5 mM GPRP substantially blocked the amount of fibrin that co-

deposited with the platelets (Figure 5-4C-E). This indicated that fibrin monomer at 230 nM
was outcompeted for platelet binding by ~8000 nM fibrinogen in the whole blood. In
contrast, 230 nM soluble fibrin polymer added to whole blood was able to co-deposit with
platelets, even in the presence of normal levels of fibrinogen. Consistent with a defect in
collagen-induced platelet activation via GPVI, the presence of soluble fibrin polymer (HBS
control condition) caused a substantial reduction of platelet deposition on collagen (Figure
5-4B-E), especially after ~100 seconds when ADP and thromboxane release are
especially important for platelet buildup [110]. GPVI is not required for firm adhesion to
collagen but does lead to strong calcium mobilization to drive granule release, α2β1
activation, COX-1 activation, and αIIbβ3 activation required to support secondary
aggregation.
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Additional evidence from pairwise agonist scanning [109] found that exposure of
apixaban-treated platelet-rich plasma (12% PRP) to thrombin (1-10 nM) for 500 seconds,
but not ADP or thromboxane mimetic U46619 exposure, dramatically blocked subsequent
GPVI activation by convulxin or collagen-related peptide. The onset of convulxininsensitivity required 200 to 500 seconds of thrombin exposure, was not mimicked by
exposure to PAR-1/4 activating peptides, was not observed with washed platelets, and
was blocked by fibrin polymerization inhibitor (GPRP) or Factor XIIIa inhibitor (T101),
which is consistent with soluble fibrin binding GPVI. Since only 1% conversion of plasma
fibrinogen generates 90 nM soluble fibrin (which exceeds ~1 nM GPVI in blood), circulating
platelets in coagulopathic blood may display an acquired GPVI-deficiency that impacts
hemostasis, even for transfused platelets.
Distinct from the role of intrathrombus generation of fibrin, low levels of non-gelling,
soluble fibrin may function differently in the context of trauma to cause an acquired GPVIdeficiency in the systemic circulation. Under flow conditions, platelets exposed to soluble
fibrin species displayed less accumulation on a surface of fibrillar collagen. Generation of
low and transient levels of thrombin in coagulopathic blood may generate circulating
soluble fibrin able to bind platelet GPVI to cause platelet insensitivity to stronger GPVI
agonists such as collagen of the damaged vessel wall. Understanding mechanisms behind
platelet hypofunctionality may be relevant to transfusion therapies, and other clinical
interventions.
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Figure 5-4: Under thrombin-free conditions, presence of soluble fibrin in whole
blood reduces platelet adhesion on collagen under flow
(A) Schematic of experimental protocol. Fluorescent fibrinogen was exposed to 2.5 nM
thrombin with either 5 mM GPRP (inhibit fibrin formation) or HBS (control). After 300 s, the
thrombin was quenched with 100 μM PPACK. This reacted fibrinogen/fibrin solution was
diluted by a factor of 10 into PPACK/apixaban-inhibited whole blood with either 5 mM
GPRP or HBS and then perfused through an 8-channel microfluidic device at 200 s-1 over
a collagen surface. (B) GPRP increased platelet deposition on the collagen surface after
60 s. (C) Fibrin co-deposition with platelets was significantly decreased with 5 mM GPRP.
(D) At 120 s, soluble fibrin monomer (GPRP present) resulted in more platelet deposition
to collagen, while soluble fibrin polymer (no GPRP) resulted in less platelet adhesion to
collagen. (E) At 240 s, platelet deposition and aggregation on collagen was quite
pronounced in the presence of GPRP which blocked fibrin co-deposition, as expected
[109].
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CHAPTER 6: FUTURE WORK
6.1

Shear-Induced Platelet Activation
The impingement-post and stenosis microfluidic devices described in Chapters 3

and 6 can be used to better understand the process of shear-induced platelet activation,
including the triggers of activation, the process of activation, and how it affects single
platelet behavior.
It is currently unclear how the shear force on the platelet mechanistically translates
to outside-in signaling and activation. Blebbistatin, a myosin II inhibitor, could be used to
see if platelet retraction against the VWF substrate is responsible for SIPA. If the pulling
force of platelets against VWF is necessary for activation, we would expect decreased
activation in blebbistatin treated platelets.
To understand when the effect of SIPA begins, it is important to find the critical
shear rate to get calcium mobilization, phosphatidylserine exposure, and/or P-selectin
exposure on adherent platelets when bound to fibrous and adsorbed VWF. By measuring
the fluorescence of multiple markers of activation, such as calcium dye, Annexin V, and
P-selectin antibody, while increasing the shear rate in a stepwise fashion, it is possible to
determine the multiple stages of platelet activation and their implications in thrombus
growth. One complication to this study would be that it is unclear whether the amount of
time at a given shear rate has a significant effect on platelet activation. For instance, if a
platelet experiences a lower shear rate of 1000 s-1, will it take longer to activate, reach a
certain level of activation and stop, or will it not activate at all? If the shear rate is increased
to 5000 s-1 after experiencing 1000 s-1 for some number of minutes, are the platelets more
likely to stay adherent to the VWF due to a higher activation level, or will they simply reach
a higher level of activation? Though these sudden shifts in shear rate are unlikely to occur
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in vivo, this kind of experimentation will help us better understand the on-off process of
platelet binding to VWF fibers, enabling better models of thrombus formation. To account
for this difficulty, a series of experiments comparing the 3 activation measures at different
shear rates, different shear increase steps, and different times at each shear, a more
complete image of the effect of shear rate over time on platelet activation can be
assembled.
It is known that more highly activated platelets are more strongly adherent, but the
exact nature of this relationship is still unknown. Using fluorescent video capture, single
platelets bound to VWF fibers or patterned VWF can be tracked for their response to shear
exposure over time. By correlating extent of activation with the likelihood that a platelet
will fall off of the VWF, it is possible to quantify the adhesion strength of activated platelets
on VWF fibers, which could inform how steady state VWF-platelet aggregates form in
thrombosis. The information from this study would be directly applicable in simulations of
thrombus formation.
Since VWF adhesion to collagen during the beginning stages of clotting also
occurs at high shear, it is important to determine the effect of SIPA on collagen/VWF
surfaces. Some preliminary work has been done in patterning 100 μm wide strips of
collagen, VWF, or collagen/VWF on a glass slide, and using a 60 μm wide stenosis device
to perfuse PPACK/apixaban WB at 1000 s-1 or 5000 s-1 for 7 minutes (Figure 6-1A). By
measuring platelet adhesion and P-selectin exposure as a marker of activation, the
importance of substrate in SIPA can be measured. Since platelets had to firmly adhere
first in order to display P-selectin, the platelet adhesion behavior on these surfaces was
quantified (Figure 6-1B). At 1000 s-1, patterned VWF alone was not sufficient for platelet
adhesion, but both collagen and collagen/VWF supported significant platelet adhesion,
87

with the collagen/VWF condition leading to more platelet accumulation at longer times.
When WB was instead perfused at 5000 s-1, platelet adhesion on the collagen surface was
severely reduced to the level of patterned VWF. However, collagen/VWF was able to
support stable platelet adhesion. This result is not a surprise, since it is well known that
VWF is needed for platelet adhesion at higher shear rates, but the accompanying platelet
activation does begin to tell an interesting story.
When the platelet activation pattern is examined, it is evident that platelets bound
to collagen/VWF surfaces are not significantly different than platelet bound to collagen
surfaces at 1000 s-1 (Figure 6-1C). However, when the prevailing shear rate is 5000 s-1, a
higher ratio of platelets are activated to the point of P-selectin exposure, and are activated
throughout thrombus formation. Though this seems to be partially driven by the lower
numbers of adherent platelets at 5000 s-1, those that do stick are likely more activated and
have more bonds with the VWF on the surface to withstand the high shear forces in the
free blood flow. In contrast, there was no P-selectin exposure in the collagen condition at
5000 s-1. The platelets aren’t able to form high shear bonds with GPIb on collagen,
resulting in less platelet deposition at high shear. Additional experiments are necessary to
determine how much of an effect the addition of VWF to collagen has on platelet activation.
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Figure 6-1: Shear-induced platelet activation on collagen/VWF surfaces
(A) PPACK/apixaban WB was perfused over a collagen or collagen/VWF surface at 1000
s-1 or 5000 s-1 for 7 minutes. (B) At 1000 s-1, there was increased adhesion of platelets on
the collagen/VWF surface than either collagen or patterned VWF surfaces alone. At 5000
s-1, collagen/VWF was the only surface that was able to accumulate platelets away from
the slower flow on the edges of the channel, since VWF is required for platelet adhesion
at high shear. (C) Using P-selectin as a marker for platelet activation, it was observed that
shear-induced platelet activation dominates at 5000 s-1. No significant activation was
observed in the collagen condition at 5000 s-1 due to an overall lack of platelet adhesion.
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There are a couple factors that may be having an effect. First, since the VWF
patterned on top of the collagen is done so in an adsorptive manner, it is not clear if the
VWF availability to platelets in flow is the same as VWF deposited on collagen surfaces
at high shear rates. To test this, VWF fibers can be deposited at high shear rates on a
patterned collagen surface. After VWF fibers are detected on the surface, whole blood can
be perfused at high shear rates to measure adhesion and activation on this more
physiologically relevant substrate as a function of VWF deposited. There also may be an
alignment effect of VWF, where VWF fibers aligned with flow (similar to in vivo) may be
able to better bind and capture platelets due to closer downstream proximity to
platelet/VWF binding sites. Second, because WB is perfused at high shear rates in this
experiment, there may be some VWF deposition on either collagen or on top of platelets,
as previously seen in Colace et al. [38]. To measure this, VWF in WB can be labeled with
a fluorescent antibody, so any additional VWF deposition above the initial baseline can be
quantified as the thrombus grows. Since these clots are formed at a constant flow rate,
we would expect VWF deposition to occur at the beginning of the experiment on the
exposed collagen surface, and again later in the experiment at the top of the thrombi,
since shear rates here will be elevated as the thrombus occludes the channel.
Since thrombin was inhibited in the preliminary results to remove thrombin-based
platelet activation, it is not clear how significant of a role thrombin plays at high shear
rates. One hypothesis would be that thrombin washes out too quickly at high shear rates
to have as significant of an effect, but platelets close to the point of thrombin generation
(primarily in the core) may still be affected. If this is the case, then the in vivo mechanism
for SIPA would be more important at the top of the clots, where thrombin has limited
access due to flow conditions. A set of experiments where thrombin is not inhibited would
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help to determine if the activation of platelets in high shear thrombus formation is
significantly different with thrombin, further elucidating its role at high shear.
6.2

Effect of N-Acetylcysteine on VWF aggregation
Since NAC was unable to dissolve thick VWF fibers formed in the impingement-

post microfluidic device [19], it is unclear if NAC is only effective when VWF fibers are
thinner, such as when crosslinking platelets. Though de Lizarrondo and colleagues [4]
provided some in vivo evidence that NAC targets the VWF crosslinking arterial thrombi, it
is not clear whether NAC actually cleaves VWF multimers within the clot, or if it merely
interferes with the VWF/platelet interactions in the formation of the top of the clot. A few
experiments may be able to provide greater clarity into these two potential hypotheses.
To distinguish between these mechanisms, the formation of VWF-rich clots on the
post of the impingement-post microfluidic device can be used. By perfusing citrated whole
blood (WB) through the device at 10,000 s-1 with and without NAC, it will be possible to
compare the size of the platelet/VWF accumulation to determine if NAC is interfering with
the platelet/VWF interactions in the formation of the clot. Since NAC has been shown to
reduce the multimer sizes of circulating VWF, we would expect NAC would result in
smaller clots at steady state. Although this experiment alone cannot determine the
mechanism, it can be used in conjunction with the following experiments to triangulate the
role of NAC in this system.
To test the VWF cleavage hypothesis, a platelet/VWF clot can be formed using
citrated WB, followed by citrated WB with NAC. If the thrombus size decreases over time,
NAC is likely cleaving VWF crosslinks between the platelets, since no collagen or fibrin is
present in this experiment. To confirm this result, a clot formed on a collagen surface at
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high shear can be challenged with NAC to see if the VWF shell of the clot dissolves in the
presence of NAC, while the primarily platelet/collagen interactions of the core remain
stable.
These experiments would provide valuable insight into the potential uses of NAC
as an antithrombotic therapy in diseases like coronary artery disease or stroke. If NAC
primarily interferes with platelet/VWF interactions during clot formation, it could be used
as a preventative measure to prevent smaller thrombi from propagating to fully occlusive
clots as they are exposed to higher shear rates. Initial results from de Lizarrondo and
colleagues suggest that NAC does not work as a preventative treatment in the ferric
chloride injury model [4], but since the formation of ferric chloric thrombi is rapid and driven
by oxidative stress [111], there may be a kinetic argument for the potential efficacy of NAC
in stroke prevention. This hypothesis could be tested by measuring growth rates of thrombi
in microfluidico either from initial platelet adhesion or as a treatment in blood for growing
thrombus that is growing to reach occlusion.
However, if NAC does act as a thrombolytic agent by cleaving VWF/VWF bonds
or VWF/platelet bonds, then it has potential to be used in more occlusive vessels to reduce
the size of nearly occlusive clots, as demonstrated in the ferric chloride mouse model [4].
It is, of course, possible for both mechanisms to be important, which would only improve
NAC’s potential as a treatment for ischemic stroke.
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CHAPTER 7: CONCLUSION
Microfluidic techniques enable the study of thrombosis in flow environments that
mimic the pathological environment of many thrombotic diseases. Using these techniques,
we find that the aggregation of VWF multimers into fibers paired with bound platelet
activation under shear to be significant contributors to the formation of thrombi under high
shear conditions.
In Chapter 1, we review important mechanisms of thrombus formation, including
the roles of platelets, coagulation, VWF, and hemodynamics. These concepts serve as a
background for the other sections to give an idea of the many mechanisms involved
simultaneously in clot formation. In Chapter 2, a guide for designing new microfluidic
devices was compiled, including descriptions of common features and important design
considerations for making a new device. Using this chapter as a guide, new devices can
be developed in the future to better understand the mechanisms involved in thrombosis.
In Chapter 3, the impingement-post device was developed to study fibrous VWF
and its role in coagulation and platelet thrombus formation. This device was the first to
isolate aggregated VWF fibers without the use of collagen. It was found that fibrous VWF
is non-amyloid, resistant to ADAMTS13 and tPA, and captures FXIIa during aggregation
allowing coagulation to proceed on its surface. Platelets also bind and activate on the
surface of VWF fibers in a shear-dependent manner. In Chapter 4, the stagnation point
device was developed to study the formation of thrombi at stagnation points relevant to
reattaching flows. These clots were found to have a core-shell structure, were VWF-rich,
and were sensitive to the addition of NAC, suggesting that platelet/VWF interactions were
crucial for clot stability. However, fibrin polymerization was not required for stable
thrombus formation in this flow geometry.
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In Chapter 5, a series of side projects were discussed, including the shear-induced
platelet activation on VWF, the effect of NAC on thrombus formation, and the effect of
soluble fibrin on GPVI activation by collagen and its role in trauma. When studying shearinduced platelet activation, it was observed that platelet activation was not primarily driven
by the strain of the stretching VWF substrate, because platelets bound to both fibrous and
sorbed VWF displaced similar levels of activation. In studying the effect of NAC on
thrombus formation, it was found that NAC reduces VWF deposition on collagen, with a
smaller average fiber length and smaller volume of VWF fiber deposition on the collagen
surface. In studying GPVI in trauma-like conditions, soluble fibrin led to decreased platelet
deposition on collagen, which in conjunction with calcium assays, suggest soluble fibrin
can reduce GPVI binding by collagen. In Chapter 6, some future experiments were
suggested to gain greater clarity about the mechanisms involved in shear-induced platelet
activation on VWF and about NAC’s potential antithrombotic use.
Together, the findings presented here are related to many of the processes that
occur during thrombosis, including the interactions between high shear blood flow, VWF,
and platelet activation. As demonstrated in the above studies, microfluidics provide a
valuable tool for studying high shear thrombosis in a controlled setting to discover potential
mechanisms that help us predict in vivo behavior. The devices discussed in this thesis will
be valuable tools for understanding how potential therapeutics, such as NAC, affect
thrombus formation and stability.
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